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ABSTRACT 
Hind Muallem:  Association of Genetic Variations in the 3’UTR of the Human Low 
                       Density Lipoprotein Receptor with the Lipid Parameters in the      
      Atherosclerosis Risk in Communities (ARIC) Study 
(Under the direction of Nobuyo Maeda) 
 
 The low-density lipoprotein receptor (LDLR) plays a pivotal role in cholesterol 
homeostasis.  However, the role of genetic variations in the 3' UTR of the LDLR in relation 
to plasma cholesterol has been largely understudied.  Six SNPs, G44243A, G44332A, 
C44506G, G44695A, C44857T and A44964G, within the 5’ region of the 3’UTR fall into 
three common haplotypes, GGCGCA, AGCACG, and GGCGTA, occurring at frequencies of 
0.45, 0.31 and 0.17 respectively in Caucasians (n=29) and 0.13, 0.13 and 0.38 respectively 
in African Americans (n=32), with three other haplotypes occurring at lesser frequencies.  
Genotyping of two “haplotype tagging” SNPs, C44857T and A44964G, in the 
Atherosclerosis Risk in Community (ARIC) study population showed that in Caucasians, 
but not in African Americans, the inferred TA haplotype had a significant LDL-cholesterol 
lowering effect.  The adjusted LDL-cholesterol levels in the TA/TA diplotypes were lower 
by 6.10 mg/dl in men (P<0.001) and by 4.63 mg/dl in women (P<0.01) than in individuals 
with other diplotypes.  Caucasian men homozygous for CA, in contrast, showed significantly  
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higher LDL-cholesterol (P<0.04), lower HDL-cholesterol (P<0.02) and higher LDL/HDL 
ratios (P<0.001).  To identify if these haplotypes are causative, we studied the expression of 
a reporter gene in a tissue culture based system carrying a 3’UTR that includes the 1kb 
nucleotide sequences corresponding to the AGCACG, GGCGTA and GGCGCA haplotypes. 
The three haplotypes of the 3’UTR sequences had no difference in their effect on the 
expression.  Therefore, the association in Caucasians with plasma lipid profiles indicative of 
higher cardiovascular risk is not caused by polymorphisms in the 3’UTR of the LDLR gene, 
but with other polymorphisms that are in linkage disequilibrium with them. 
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Hypercholesterolemia, Atherosclerosis, and Coronary Heart Diseases 
 Hypercholesterolemia is a major factor in the development of atherosclerosis. 
Atherosclerosis leading to coronary heart disease (CHD) is the cause of more than 25% of 
the deaths in the United States.  Every year around 1.2 million Americans are diagnosed 
with CHD.  Hypercholesterolemia is clearly a complex and multigenic condition.  Four main 
monogenic diseases have been identified. 
1 - Familial Hypercholesterolemia (FH) 
2 - Familial Defective Apolipoprotein B-100 (FDB) 
3 - Autosomal Recessive Hypercholesterolemia (ARH) 
4 - Autosomal Dominant Hypercholesterolemia due to mutations in PCSK9 gene 
 
Familial Hypercholesterolemia (FH) 
 Familial hypercholesterolemia (FH) is an autosomal dominant disease that is 
characterized by a hallmark of elevated low density lipoprotein cholesterol (LDL-C) and 
premature CHD.  FH is caused by mutations in the low density lipoprotein receptor gene 
(LDLR) (Hobbs et al. 1992; Hobbs et al. 1988; Levy et al. 1997; Pereira et al. 1995). 
FH heterozygote occurs 1 in 500 individuals.  Plasma LDL-C in these patients is increased 2 
fold (300-500 mg/dl).  FH homozygote is rare, occuring 1 in million.  Plasma LDL-C in FH 
homozygotes is increased 3 to 6 fold (600-1200 mg/dl).   
 LDLR is a cell surface receptor and together with its ligands ApoE / ApoB, plays a 
pivotal role in cholesterol homeostasis.  LDLR is synthesized as a glycoprotein precursor of 
120 KD, which is changed to a mature glycoprotein of 160 KD due to the addition of a 40 
KD protein (Tolleshaug et al. 1982).  It is located on chromosome 19p13.1-13.3.  It encodes 
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839 amino acids, and has multiple copies of Alu sequences of repetitive DNA (Yamamoto et 
al. 1984).  The LDLR is a member of the supergene families, since 13 out of the 18 exons of 
the gene encode proteins that are homologous to other genes, such as C9 component of 
complement, epidermal growth factor precursor, and blood clotting system factor XI and X 
(Sudhof et al. 1985). 
 The LDLR is made up of five domains.  The first domain is the ligand binding region 
for ApoE and ApoB-100, which consists of seven repeats rich in cysteine.  The second 
domain is the epidermal growth factor-precursor homology domain which is required for the 
dissociation of the ligand in the acidic medium of the endosome.  The third domain is the O-
linked glycan region.  The fourth domain is the transmembrane domain that anchor the 
LDLR in the lipid bilayer, and the fifth domain is the cytosolic region which is involved in 
endocytosis and internalization of the LDL-LDLR complex (Gent and Braakman 2004; 
Sudhof et al. 1985) (Figure 1.1). 
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Figure 1.1.  Structure of the human low density lipoprotein receptor.  On the right are the 
exons encoding the protein and on the left are the domains of the mature protein. 
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 Mutations in the LDLR lead to an elevated level of total cholesterol and LDL-C 
(Hobbs et al. 1992).  There are two classified groups of LDLR mutations:  1) Receptor 
negative or null mutations, and 2) receptor defective mutations.  Within these groups there 
are five different classes of LDLR mutations (Austin et al. 2004; Gent and Braakman 2004). 
 Class 1:  This is called a receptor negative mutation.  The LDLR synthesis is 
disrupted due to different mutations leading to a complete absence of functional protein. 
 Class 2:  Normally the LDLR is synthesized as 120 KD in the endoplasmic reticulum 
(ER) and then migrates to the Golgi where the O and N sugars are added to change it to 160 
KD protein.  In a class 2 mutation the protein does not leave the ER and is not transported to 
the Golgi.  As a result it is degraded before it is transported to the cell surface. 
 Class 3:  The LDLR is synthesized and transported to the cell surface, but does not 
properly bind the low density lipoprotein particle (LDL).  This is caused by deletions or 
mutations in the ligand binding domains. 
 Class 4:  The surface receptor is not clustered in coated pits, and as a result can not 
internalize the bound LDL particle into the cell.  This is caused by mutations in the 
cytoplasmic domain. 
 Class 5:  Mutations occur in the epidermal growth factor homology domain which 
hinders the dissociation of the receptor and ligand in the endosome in an acidic environment.  
This decreases the recycling of the receptor to the cell surface. 
Class I is referred to as a receptor negative mutation while the other 4 classes are referred to 
as receptor defective mutations. 
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 All of the above class mutations cause an impaired function of the LDLR which 
leads to FH and to abnormal clearance of cholesterol and LDL-C from the circulation, and 
hence an increased risk of atherosclerosis. 
 
Familial Defective Apolipoprotein B-100 
 Apolipoprotein B-100 (ApoB-100) is synthesized in the liver; it is made up of 4536 
amino acids, and weighs 550 KD.  ApoB-100 plays an important role in LDL clearance.  It 
is the only protein constituent of LDL and is the ligand that is recognized by the LDLR.  
Genetic disorders of ApoB-100 cause familial defective apolipoprotein B-100 (FDB), a 
disorder which leads to hypercholesterolemia and an increased risk of CHD (Innerarity et al. 
1990).  The first identified mutation in ApoB-100 was a single base substitution in exon 26 
at position 3500.  This single base substitution (G/A) CGG to CAG, leads to the amino acid 
substitution of glutamine for arginine (R3500Q) (Innerarity et al. 1990; Jacobsen et al. 2002; 
Soria et al. 1989).  The frequency of the mutation is 1/500 in Caucasians.  The mutation 
reduces the affinity of LDL to LDLR by approximately 95 %, resulting in 
hypercholesterolemia (Tybjaerg-Hansen et al. 1998). 
 Along with the role of ApoB-100 in mediating the clearance of LDL, it is also 
required for the synthesis, assembly and secretion of the hepatic triglyceride rich lipoprotein 
particle, very low density lipoprotein (VLDL), into the circulation.  A full length ApoB-100 
is needed for normal secretion of VLDL.  Mutations in the coding region of the gene result 
in a premature termination codon (Burnett et al. 2003; Burnett et al. 2007; Linton et al. 
1992).  Most of these nonesense or frame shift mutations cause a truncated ApoB-100.  
Truncation could vary in size from B-2 to B-89.  Short truncations of B-27/B29 are not 
 7 
detectable in plasma because they are not secreted into the circulation (Lancellotti et al. 
2004; Schonfeld 2003).  Hence, these mutations are cause of familial 
hypobetalipoproteinemia (FHBL).  FHBL is a genetic disorder that is characterized by low 
levels of plasma cholesterol, LDL-C and ApoB. 
 For example a nucleotide change (G/T) in the 5’splice donor site in intron 5 leads to 
improper splicing and results in the absence of plasma ApoB-100.  Another nucleotide 
change (C/T) in exon 10 at residue 412 causes a nonsense mutation leading to a truncated 
ApoB-100 (Huang et al. 1991).  A novel missense mutation (R463W) was discovered in a 
Lebanese Christian (Burnett et al. 2003).  The homozygotes of this mutation have very low 
levels of ApoB-100 that is barely detectable in plasma. 
Also, a new mutation, (R3480P), was discovered in 2005.  Heterozygotes of this mutation 
have a lower binding affinity to LDLR yet, they have hypobetalipoproteinemia.  This is 
mainly due to the reduced amount of VLDL that is converted to LDL (Benn et al. 2005). 
 
Autosomal Recessive Hypercholesterolemia (ARH) 
 The ARH gene encodes a putative adaptor protein called ARH.  Its main function is 
to link the LDLR to the clathrin protein of the coated pit for endocytosis.  ARH is made up 
of 308 amino acids and four domains, an N-terminal domain, of unknown function, a 
phosphotyrosin binding domain (PTB) that binds the
 
(FDNPVY) sequence in the LDLR 
cytoplasmic tail for internalization, a clathrin box sequence that binds with high affinity to 
clathrin, and a C- terminal domain that binds to the adaptor protein -2 (AP-2).  Therefore, 
ARH mediates the interaction of the three proteins, LDLR, clathrin, and AP-2 to promote 
the clustering and endocytosis of the LDL-LDLR complex (Garuti et al. 2005; He et al. 
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2002).  ARH is tissue specific since it is required for LDLR function in the liver but not in 
fibroblast. 
 Mutations in the ARH gene cause autosomal recessive hypercholesterolemia, (ARH) 
a disorder characterized by impaired internalization of LDLR in the liver.  Clinically, it is 
similar to familial hypercholesterolemia which is caused by mutations in LDLR gene.  ARH 
is a very rare disorder worldwide.  Around 50 recognized affected ARH individuals are 
mainly of Sardinian or Middle Eastern origin (Arca et al. 2002).  The two mutations that 
were found in the Sardinian population are a nonsense mutation at G65A, which led to a 
stop codon at W22X, and an insertion at 432insA which also led to a truncated non 
functional protein (Garcia et al. 2001).  In affected Lebanese individuals the prevalent 
mutations are a nonsense mutation at C406T, resulting in a stop codon at Q136X, and 
another missense mutation at C605A resulting in a stop codon at P202H (Garcia et al. 2001; 
Soutar et al. 2003). 
 
Autosomal Dominant Hypercholesterolemia due to mutations in PCSK9  
 In the past few years, a newly discovered serine protease called proprotein 
convertase subtilisin–like kexin type 9 (PCSK9) was shown to play an important role in 
LDL metabolism.  PCSK9 is a glycoprotein that encodes 692 amino acids.  It has N-terminal 
prodomain, a catalytic domain and a C-terminal domain (Benjannet et al. 2004; Naureckiene 
et al. 2003; Seidah et al. 2003).  In 2003, Abifadel et al reported that some missense 
mutations in the gene cause autosomal dominant hypercholesterolemia (Abifadel et al. 
2003).  Since then, more research was done to elucidate the mechanism by which PCSK9 
plays a role in lipoprotein metabolism.  Some studies have shown that over expression of 
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PCSK9 in the liver of mice has no effect on the mRNA of LDLR, but, reduces LDLR by 
degrading it post transcriptionally (Fasano et al. 2007; Horton et al. 2007; Maxwell and 
Breslow 2004; Maxwell et al. 2005).  The actual site of action of PCSK9 has not yet been 
identified.  However, Helen Hobbs and her group showed that stable over expression of 
PCSK9 has no effect on either synthesis of LDLR or trafficking of LDLR out of the 
endoplasmic reticulum in HepG2 cells (Horton et al. 2007).  Also, inhibition of the 
proteosome does not affect LDLR reduction by PCSK9, but disassembly of the Golgi 
complex did inhibit the degradation of LDLR (Horton et al. 2007).  They also showed that 
the addition of purified PCSK9 to the medium in HepG2 cells decreased the number of 
LDLR on the cell surface, and that both proteins are co-immunoprecipitated.  This suggests 
that the two proteins are physically attached and that PCSK9 functions extracellularly.  In 
addition, the ARH that is required for the internalization of LDLR is also required for the 
degradation of LDLR by PCSK9.  Hence, the absence of ARH inhibits the degradation of 
LDLR by PCSK9 (Lagace et al. 2006). 
 Based on the findings mentioned above, a possible mechanism in which PCSK9 
causes LDLR degradation is through binding to LDLR on the cell surface in a catalytically 
inactive state.  In the endosome, the pH is acidic and PCSK9 becomes active and degrades 
the LDLR.  Another possible mechanism is that PCSK9 inhibits normal recycling of LDLR 
after internalization, and instead directs LDLR to the lysozome where it is degraded rather 
than recycled to the cell surface. 
 Having shown the importance of PCSK9 in lipoprotein metabolism, we would 
expect that mutations in the gene also affect plasma levels of LDL-C.  Many researchers 
have shown that missense and nonsense mutations in the gene that cause loss of PCSK9 
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function are associated with hypocholesterolemia (Abifadel et al. 2003; Chen et al. 2005).  
Other missense mutations that cause gain of function are associated with 
hypercholesterolemia.  Loss of function mutations are more common than gain of function 
mutations (Fasano et al. 2007; Kotowski et al. 2006; Zhao et al. 2006).  Examples of gain of 
function mutations are S127R in the prodomain, F216L(Abifadel et al. 2003), D374Y (Leren 
2004; Timms et al. 2004) N425S in the catalytic domain, and R496 in the C terminal 
domain.  Some known loss of function mutations are R46L, ∆R97 (Zhao et al. 2006), 
G106R (Berge et al. 2006), Y142X (Cohen et al. 2005) in the prodomain, L253F in the 
catalytic domain, A443T (Kotowski et al. 2006) and C679X (Benjannet et al. 2006) in the C 
terminal domain.  There are also other missense mutations and in-frame deletions that cause 
low levels of LDL-C (Berge et al. 2006; Cameron et al. 2006; Kotowski et al. 2006). 
 Hypocholesterolemia that is caused by loss of function mutations is not associated 
with diseases, as it is benign, unlike abetalipoproteinemia and homozygous 
hypobetalipoproteinemia, both of which are associated with hepatic steatosis, malnutrition 
and fat-soluble vitamine deficieny.  Hence, PCSK9 is considered a good therapeutic target 
for lowering LDL-C and prevention of coronary heart disease. 
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Lipoprotein Metabolism 
 Lipoprotein particles are made up of apoproteins and lipids, and facilitate the 
transport of lipids in the aqueous medium of the plasma.  They are spherical in shape with a 
hydrophobic core of cholesterol esters and triglycerides, surrounded by a polar layer of 
phospholipids and hydrophilic proteins.  There are six classes of lipoproteins: chylomicrons, 
chylomicron remanents, very low density lipoprotein (VLDL), intermediate density 
lipoprotein (IDL), low density lipoprotein (LDL) and high density lipoprotein (HDL) 
(Figure 1.2) http://images.google.com. 
Chylomicrons are assembled in the intestinal mucosa and they transport dietary 
cholesterol and triglycerides from the intestine to the liver and other tissues.  They carry 
apoB-48 and apoE on their surface.  Chylomicron remnants deliver dietary cholesterol, 
apoB-48 and apoE to the liver via the chylomicron remanent receptor.  VLDL transport 
endogenous triglycerides and cholesterol to extra hepatic tissues, mainly muscle and adipose 
tissue, as a source of energy or for storage.  They have apoE, apoC, and apoB-100.  IDL are 
formed when triglycerides are removed from VLDL.  They are either taken by the liver or 
are converted to LDL.  LDL is the main carrier of cholesterol to the tissues in humans.  It 
has only apoB-100.  HDL transports cholesterol from the tissues back into the liver for 
excretion in bile.  They have apoE, apoC, and apoA. 
 Cholesterol plays an important role in body functions.  It is an important component 
of cell membranes as well as a precursor of steroid hormones, estrogen, androgen, 
mineralcorticoids and glucocorticoids.  Estrogen and androgen are produced by the adrenal 
cortex and the gonads; they are responsible for the function of female and male secondary 
sex organs.  Mineralcorticoids and glucocorticoids are both formed in the adrenal cortex.  
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Mineralcorticoids maintain water and salt balance, while glucocorticoids affect fat, 
gluconeogenesis, glycogen, and protein degradation. 
Cholesterol is also a precursor of bile acids which are synthesized in the liver.  They are 
stored in the gallbladder and then secreted into the small intestine to render dietary lipids 
soluble for absorption. 
Since lipids are insoluble in plasma, they are transported via lipoprotein through three major 
pathways (Figure 1.2). 
       1.-..Exogenous pathway 
       2.-..Endogenous pathway 
       3.-..Reverse cholesterol pathway. 
Exogenous pathway 
 Dietary lipids are insoluble in the aqueous environment of the small intestine.  They 
become soluble through the action of bile acids, which are secreted from the liver.  Once 
solubilized they become accessible to pancreatic lipase which hydrolyzes dietary 
triglyceride (TG) into free fatty acids (FFA) , and mono and diacyl glycerol (Dawson and 
Rudel 1999).  These products diffuse into the intestinal epithelial cells where they are 
resynthesised as TG.  The entrocytes package the cholesterol, TG, and phospholipids into 
chylomicrons which enter the circulation via the lymphatic system.  Before entering the 
circulation, apolipoprotein B-48 (ApoB-48) apolipoprotein A (ApoA) A-I, II and IV are the 
predominant apolipoproteins on the chylomicrons.  ApoB-48 is synthesized only by the 
small intestine and is generated by a stop codon at postion 2153 of the ApoB mRNA which 
results in 48 % of the full length of ApoB-100.  In the blood stream they acquire 
apolipoprotein E (ApoE), Apolipoprotein C (ApoC) CI, CII and CIII from other 
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lipoproteins, mainly high density lipoproteins (HDL) (Tall 1990).  In the capillaries of 
muscle and adipose tissue, lipoprotein lipase hydrolyzes the TG in chylomicrons into FFA 
and glycerol.  The FFA is used as a source of energy for muscles and peripheral tissues, or is 
stored in adipose tissues in the form of TG.  The chylomicron remnants, i.e. cholesterol and 
apoproteins, are taken up by the liver by the chylomicron remanent receptor called low 
density lipoprotein receptor –related protein (LRP) (Mahley and Ji 1999) 
 
Endogenous pathway 
 While fasting, the liver becomes the main source of plasma lipoproteins.  Excess 
dietary lipids are stored in the liver in the form of triglycerides.  The lipids are packaged into 
a VLDL particle that has ApoB-100 and is secreted into the plasma through the space of 
Disse.  Like chylomicrons, the lipoprotein lipase converts VLDL to intermediate density 
lipoprotein (IDL).  The IDL are removed by the liver via the LDLR.  As the IDL lose more 
TG, they are converted into smaller, denser, cholesterol- ester rich LDL particles.  LDL is 
the main plasma carrier of cholesterol to tissues.  They do not contain ApoE on their surface 
and can be removed solely by the ApoB -100 ligand.  ApoB -100 has a lower affinity for the 
LDLR than ApoE, which leads to higher plasma half life of circulating LDL.  The LDL is 
taken up by the tissue through LDLR by endocytosis.  The maximum uptake is in the liver, 
which accounts for 75%, and in the adrenals and adipose tissues (Goldstein and Brown 
1984; Rudel et al. 1986).  Inside the peripheral cell the apoproteins are degraded and 
cholesterol esters are hydrolyzed to give free cholesterol which is incorporated into the 
plasma membrane and used for the synthesis of steroids.  Excess cholesterol in the liver is 
excreted in the form of bile acids.  When LDL circulates for a long time in circulation, it is 
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oxidized and is taken up the macrophage scavenger receptor, which can lead to the 
formation of foam cells in the vessel wall (Quinn et al. 1987).  
 
Reverse Cholesterol pathway 
 HDL is another class of lipoproteins.  HDL is synthesized in the liver and small 
intestine, has ApoCI, ApoCII and ApoA1 on its surface, and plays an important role in 
reverse cholesterol transport.  It removes extra cholesterol from the tissues and returns them 
to the liver by three different pathways.  One pathway is the transfer of cholesterol to LDL 
and VLDL via the cholesterol ester transfer protein (CETP).  The second pathway is through 
the accumulation of ApoE on the HDL particle and then clearance by direct binding to the 
LDLR through ApoE.  Thirdly, the cholesterol is taken up directly by the scavenger receptor 
(SR-B1) without the uptake of particles (Acton et al. 1996; Steinberg 1996). 
 Taken together we conclude that cholesterol carried by high non-HDL particles in 
circulation is associated with high risk for CHD while, cholesterol carried by HDL particles 
is associated with low risk of CHD. 
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Figure 1.2.  Human Lipid Metabolism.  The lipid metabolism is divided into three 
pathways, the exogenous pathway (left) which transport dietary lipids, the endogenous 
pathway (right) which transports lipids from the liver to the circulation and the reverse 
cholesterol transport (lower right). 
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Regulation of the LDLR gene 
Two regions are known to regulate transcription of the LDLR gene, the Promoter 
region and downstream of the gene (Figure 1.3). 
Transcriptional elements in the promoter region lies within 177 base pair which consist of 
two TATA boxes and three GC rich imperfect repeats of16 bp in length each (Sudhof et al. 
1987).  Repeat 1 and 3 contain binding sites for SP1 transcription factor and they are 
responsible for the basal level of LDLR expression, repeat 3 contains a sterol regulatory 
element binding site (SRE-1) where sterol regulatory binding protein binds and enhances 
transcription (Briggs et al. 1993).   
The transcription of the gene is regulated by the intracellular level of cholesterol 
(Smith et al. 1990).  When the intracellular level of cholesterol is low, LDLR transcription is 
increased, and its amount on the cell surface is also increased, to actively bind and 
internalize LDL-C.  On the other hand, when the cholesterol level within cells is high, 
transcription is diminished and the uptake of LDL-C is suppressed (Dawson et al. 1988).   
This regulation depends on sterol regulatory element binding protein (SREBP) which binds 
to (SRE-1) in repeat 3 (Briggs et al. 1993).  Nuclear localization of SREBP is regulated by 
another protein called steroid regulatory element binding protein cleavage activating protein 
(SCAP).  SCAP has a sterol sensing domain (SSD), and when intracellular sterol content is 
low, SCAP activates site -1 protease (SIP) which cleaves SREBP at one site.  The cleaved 
product is then cleaved by site-2 protease, and the active N-terminal domain of SREBP 
migrates to the nucleus to start transcription (Hua et al. 1993; Wang et al. 1994).  When 
intracellular cholesterol is high, SCAP inactivates SIP and hence inhibits the cleavage of the 
N-terminal domain (Dawson et al. 1988).   
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In addition to the enhancer activity in the promoter of LDLR, Wang et al identified a 
DNA sequence highly conserved among primates approximately 13 kb downstream of the 
gene.  This PS2 sequence contains SRE binding motif TCACCCCAC which binds SREBP-
2.  The PS2 sequence enhances luciferase gene expression driven by the proximal human 
LDLR promoter.  The activity of the test vector containing LDLR promoter/SREBP-2/PS2 
was 5 fold higher than the vector containing LDLR promoter (Wang et al. 2006). 
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TATA box 
SP1 SP1 
 
Repeat 1 Repeat 2 Repeat 3 
Figure 1.3.  The sequences that regulate the transcription of the LDLR gene are localized in 
177 bp upstream of the initiation codon (AUG), mainly two TATA boxes and three direct 
repeats.  Repeat 1 and repeat 3 bind Sp1 which governs the basal level of transcription, 
while repeat 2 binds SREBP that drives cholesterol mediated regulation of the transcription. 
 
SREBP 
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Polymorphisms in the human LDLR and plasma lipid parameters 
 While mutations that render the LDLR gene defective cause familial 
hypercholesterolemia (FH), an inherited autosomal dominant disease with hallmarks of 
elevated plasma LDL-C levels and premature CHD, most individuals who suffer from CHD 
do not have FH and their plasma lipoprotein levels are within the reference range, there is 
unequivocal evidence that lowering serum cholesterol reduces the risk of CHD events (van 
Aalst-Cohen et al. 2004).  Because of its pivotal role in lipid metabolism, polymorphisms 
rendering LDLR coding sequence changes, as well as quantitative change of LDLR 
expression are a candidate risk factor for CHD, justifying association studies of common 
genetic variations in the gene. 
 Several studies have shown associations between genetic variations in LDLR and 
plasma levels of LDL-C (Ahn et al. 1994; Klausen et al. 1993; Poledne et al. 1993; Taylor R 
1988).  For example, an association between high plasma LDL-C levels and the absence of a 
Pvu II restriction sites in intron 15 has been reported in normolipidemic Norwegian and 
German populations (Pedersen and Berg 1988; Pedersen JC 1988; Schuster et al. 1990).  In 
addition the presence of AvaII site in exon 13 has been reported previously to be associated 
with increased LDL-C levels in Italian population, Hispanics and non-Hispanics and 
Brazilian whites.(Humphries et al. 1991; Salazar et al. 2000). Recently a new study has 
shown that a SNP in exon 12 ( rs 688) is associated with increased total and LDL-C in 
women (Zhu et al. 2007). 
 To date, there is no completed study on the association of polymorphisms in the 
3’UTR regulatory region of the gene.  Towards this goal, is my chapter two, I studied the 
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association of three common polymorphisms with various lipid parameters, and the effect of 
these SNPs on gene expression. 
 
Atherosclerosis risk and APOE isoforms in humans 
 Apo E, a glycoprotein of 299 amino acids, plays a pivotal role in the clearance of 
plasma chylomicron, chylomicron remnants, VLDL, IDL and HDL via its interaction with 
the LDLR and LDLR like proteins (LRP) .(Corbo and Scacchi 1999; Corbo RM 1999; 
Hussain et al. 1999; Melman et al. 2002a).  It is mainly synthesized in the liver, and to a 
lesser extent in the kidney, brain, adrenals and monocytes.  In humans, there are di-allelic 
single nucleotide polymorphisms located in exon 3 at positions T3937C and C4075T which 
together yield the three isoforms, APOE*2, APOE*3 and APOE*4, with gene frequencies of 
0.08, 0.77, and 0.15 respectively (Table 1) (Banares et al. 2005; Boerwinkle and Utermann 
1988b; - Weisgraber 1994; Weisgraber 1994) (Table 1.1). 
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             Table 1.1.  SNP position and amino acid changes in human APO gene 
SNP postion AA position AA WT   AA mutant Mutation 
3937 112 Cystein                        Arginine TGC     CGC 
4075 158 Arginine                          Cystein                 CGC    TGC 
    AA, amino acid; WT, wild type 
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These isoforms differ in the amino acids at position 112 and 158.  The most frequent 
isoform, APOE*3, has cysteine and arginine at these positions, while APOE*2 has two 
cysteines and APOE*4 has two arginines (Lund-Katz et al. 2001).  The genotype frequency 
distribution follows the same pattern in the population with E3/E3 as the highest followed 
by E3/E4, E2/E3, E2/E4, E4/E4 and E2/E2. 
 The isoforms have different binding affinities for the LDLR.  ApoE4 has a higher 
binding affinity than apoE3, while apoE2 binds very poorly (Lund-Katz et al. 2001; Saito et 
al. 2003; Saito H 2003).  Despite its poor receptor binding however, individuals with apoE2 
have a reduced level of cholesterol and a reduced risk of atherosclerosis, except for 5%–10 
% of apoE2 homozygotes who have a very high level of plasma cholesterol and exhibit Type 
III hyperlipoproteinemia (Kypreos et al. 2003.).  In contrast, individuals with apoE4 have 
slightly increased plasma cholesterol levels and an increased risk of atherosclerosis (Banares 
et al. 2005; Malloy I 2004).  This paradox in binding affinity and atherosclerosis risk has 
been explained by Davingon’s hypothesis, which states that the high binding affinity of 
apoE4 for the receptor results in rapid clearance of chylomicron and VLDL remnants, 
causing intracellular increase of cholesterol, as a consequence, there is a down regulation of 
the LDLR, while the low binding affinity of apoE2 results in slow clearance of chylomicron 
and VLDL remnants , hence low intracellular level of cholesterol, and therefore an up 
regulation of the LDLR (Davignon et al. 1988).  According to Sing and Davignon, 8.3 % of 
the total variance for LDL-C is caused by the apoE isoforms (Sing and Davignon 1985).  To 
compare the risk attributed by the different APOE isoforms, and compared to the 
homozygous APOE*3 genotype as a reference genotype, one allele of APOE*2 lowers 
cholesterol level by 10-14 mg/d, while one allele of APOE*4 raises the level by 8-10 mg/dl 
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(Hallman et al. 1991).  This difference is shown in most populations, regardless of the 
differences in the genetic background and life style such as diet and exercise. 
 
Functional gene-gene interaction between Apo E isoforms and LDLR polymorphisms:  
A determinant of lipid level variations 
Mice with humanized genes for lipoprotein metabolism 
 To test Davignon’s hypothesis that up regulation or down regulation of LDLR in 
individuals with APOE*2 or APOE*4, respectively, is the cause of the isoform-dependent 
risk for atherosclerosis, Malloy et al replaced the coding sequence of the mouse Apoe gene 
with that coding for the three human isoforms, APOE*2, or APO*E3, or APOE*4.  
Surprisingly, they found that the phenotypes of mice having the human apoE proteins are 
not the same as in humans.  Rather, they found that the three types are what would be 
expected simply from the biochemical behavior of the proteins.  Thus, the mice with human, 
apoE3 and apoE4, both of which bind to the receptor well, are normolipidemic and did not 
develp atherosclerosis on a western-type diet, while all the mice with human apoE2, which 
does not bind to the receptor well, exhibit type III hyperlipoproteinemia and develop 
atherosclerosis (Malloy I 2004).  
 Unexpectedly, and contrary to the current hypothesis, when Malloy et al increased 
expression of the LDLR in these mice, the mice with human apoE4 (4h), developed severe 
atherosclerosis due to an accumulation of cholesterol in the plasma when fed a western-type 
diet (Malloy I 2004).  This trend was not seen in mice with apoE3 (3h).  The same increase 
of LDLR, on the other hand, completely ameliorated the hyperlipidemia and atherosclerosis 
of the apoE2/E2 mice (2h) (Knouff et al. 2001).  This finding led Malloy and his group to 
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propose a new “ApoE Trapping” hypothesis: namely, that the LDLR can trap apoE4 and 
reduce its availability for transfer to newly formed lipoproteins leading to an increase in the 
plasma cholesterol concentration (Michael K. Altenburg et al. 2004). 
 The overall consequence is that increased LDLR expression has harmful effects in 
mice with apoE4.  In contrast, apoE2 with lower affinity for the LDLR virtually escapes 
trapping by the LDLR while, increased LDLR helps clearance of apoE2 enriched lipoprotein 
particles.  
 Therefore, the normal variations in the basal level of LDLR expression cause a 
difference in relative ratio of apoE/LDLR in humans as illustrated in the grey area of Figure 
1.4, and this difference determines the atherosclerosis risk in apoE isoform dependent 
fashion. 
My chapter 3 tests whether LDLR polymorphisms and human apoE polymorphisms 
interact or not in determining plasma lipoprotein profiles using ARIC population. 
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Figure 1.4.  Interaction of APOE isoforms and LDLR expression in Atherosclerosis Risk 
On the left hand side of the figure, 2m,3m and 4m represent mice that have mouse Ldlr and 
human apoE isoforms.  We see that at a normal level of expression of LDLR, the mice 
expressing human apoE2 (2m) have a higher risk of developing atherosclerosis than the 
mice expressing human apoE4 (4m) as measured by the ratio of non HDL-C/HDL-C.  The 
relative order of the risk for atherosclerosis in mice with the human apoE isoforms (2m>, 
4m>, 3m) is shown in the left side of Figure 1 
On the right hand side of the figure, 2h, 3h and 4h represent mice that carry the human apoE 
isoforms as well as one copy of the human LDLR.  When the mouse Ldlr is replaced with 
the human LDLR, the expression is increased 2.5 times.  The relationship between risk and 
APOE genotype is changed in the mice with a high level of expression of LDLR; 2h mice 
have a lower risk of atherosclerosis than the 4h mice.  The relative order of the 
atherosclerosis risk of the mice with the human receptor (2h <, 3h<, 4h) is shown in the right 
side of the figure. 
Since risk in humans with different apoE isoforms are much less, we expect that normal 
ranges of LDLR expression in humans are somewhere in the middle as shown in the grey 
box. 
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Enhancer in intron I of the human LDLR gene 
 Enhancers, by definition, are the DNA sequences where activator proteins bind to 
increase significantly the rate of transcription.  The exact location of an enhancer on a gene 
varies, and it may be located thousands of nucleotides away from the promoter of a gene.  
Also, enhancers activate transcription independent of orientation, i.e. whether they are in the 
forward or reverse direction.  Once activator proteins bind to the enhancer, they recruit 
histone acetylase transferase and ATP-dependent chromatin remodeling complex, both of 
which aid in the assembly of transcription factors at the promoter and thereby stimulate 
transcription initiation.  In some genes, enhancers are located in introns.  For example, 
enhancers have been found in intron I of HPRT gene (Reid et al. 1990), β actin 
(Frederickson 1989), adenosine deaminase (Aronow et al. 1989) and others (Banerji et al. 
1983; Basler et al. 1989; Chung and Perry 1989; Oshima et al. 1990; Reddy and Reddy 
1989; Rippe et al. 1989).  The transcriptional ability of the DNA sequence 5’ to the LDLR 
gene has been well characterized by Sudhof et al (Sudhof et al. 1987), who found that the 
1774 bp promoter sequence is sufficient for the control of LDLR gene expression.  This 
region contains a TATA box, but not CAAT box.  It also contains three short direct 
sequence repeats where steroid regulatory element binding protein (SREBP) binds.  There 
appears to be no enhancer activitiy in at least 6.5 Kb of the 5’upsream of the promoter 
region, as measured by reporter assay (Sudhof et al. 1987).  In addition to the enhancer 
activity in the promoter of LDLR, a primate-specific enhancer element PS2 was found 
downstream of the gene as mentioned earlier in the introduction (Wang et al. 2006). 
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Research Project 
 Based on the important role that the LDLR plays in the development of 
hypercholesterolemia and CHD, my specific aims were: 
 1 - To identify six common LDLR sequence polymorphisms in the 3’UTR of the 
gene and to investigate the association of the conferred common haplotypes with the lipid 
parameters in the ARIC Study.  Determine the effect of these polymorphisms on a reporter 
gene expression in cultures cells. 
 2 - Analyze gene-gene interaction between LDLR diplotypes and Apo*E isoforms in 
determining plasma lipid profile and cardiovascular risk using multiple regression analysis 
in ARIC study. 
 3 - Test enhancer activity in intron I of the human LDLR gene and identify the 
transcription factors that bind to specific sequences in the intron.  Then study the biological 
effect of the SNPs that are located in this region. 
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Abstract 
 The low-density lipoprotein receptor (LDLR) plays a pivotal role in cholesterol 
homeostasis.  However, the role of genetic variations in the 3' UTR of the LDLR in relation 
to plasma cholesterol has been largely understudied.  Six SNPs, G44243A, G44332A, 
C44506G, G44695A, C44857T and A44964G, within the 5’ region of the 3’UTR fall into 
three common haplotypes, GGCGCA, AGCACG, and GGCGTA, occurring at frequencies of 
0.45, 0.31 and 0.17 respectively in Caucasians (n=29) and 0.13, 0.13 and 0.38 respectively 
in African Americans (n=32), with three other haplotypes occurring at lesser frequencies.  
Genotyping of two “haplotype tagging” SNPs, C44857T and A44964G, in the 
Atherosclerosis Risk in Community (ARIC) study population showed that in Caucasians, 
but not in African Americans, the inferred TA haplotype had a significant LDL-cholesterol 
lowering effect.  The adjusted LDL-cholesterol levels in the TA/TA diplotypes were lower 
by 6.10 mg/dl in men (P<0.001) and by 4.63 mg/dl in women (P<0.01) than in individuals 
with other diplotypes.  Caucasian men homozygous for CA, in contrast, showed significantly 
higher LDL-cholesterol (P<0.04), lower HDL-cholesterol (P<0.02) and higher LDL/HDL 
ratios (P<0.001).  To identify if these haplotypes are causative, we studied the expression of 
a reporter gene in a tissue culture based system carrying a 3’UTR that includes the 1kb 
nucleotide sequences corresponding to the AGCACG, GGCGTA and GGCGCA haplotypes.  
The three haplotypes of the 3’UTR sequences had no difference in their effect on the 
expression.  Therefore, the association in Caucasians with plasma lipid profiles indicative of 
higher cardiovascular risk is not caused by polymorphisms in the 3’UTR of the LDLR gene, 
but with other polymorphisms that are in linkage disequilibrium with them. 
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Introduction 
 
 Low-density lipoprotein receptor (LDLR) is a cell surface receptor that mediates the 
uptake of LDL particles from the circulation via receptor-mediated endocytosis (Goldstein et 
al., 1995; Hobbs et al., 1990).  Mutations that render the LDLR gene defective cause familial 
hypercholesterolemia (FH), an inherited autosomal dominant disease with hallmarks of 
elevated plasma LDL-cholesterol (LDL-C) levels and premature coronary heart disease 
(CHD).  Although most individuals who suffer from CHD do not have FH and their plasma 
lipoprotein levels are within the reference range, there is unequivocal evidence that lowering 
serum cholesterol reduces the risk of CHD events (Gotto, 1994).  Thus, because of its 
pivotal role in lipid metabolism, a quantitative change of LDLR expression is plausibly 
associated with risk for CHD, and warrants association studies of common genetic variations 
in non-coding regions of the LDLR gene that may influence its expression at transcriptional 
or post-transcriptional mRNA levels (Sudohof et al., 1987; Wilson et al., 1998).  In addition, 
LDLR level is also determined by translation as well as protein degradation.  For example, 
genetic variations in the PCSK9 gene coding for proprotein convertase subtilisin/kexine 
Type 9, affect PSCK in protein degradation pathway, and increased PSCK activity reduces 
hepatic LDLR protein in the liver and leads to higher levels of plasma LDL cholesterol 
(Cohen et al., 2006; Kotowski et al., 2006). 
 Several studies have shown associations between genetic variations in the LDLR 
gene and plasma levels of LDL (Taylor et al., 1988; Poledne et al., 1993; Klausen et al., 
1993; Ahn et al., 1994).  For example, an association between high plasma LDL-C levels 
and the absence of a Pvu II restriction site in intron 15 has been reported in normolipidemic 
Norwegian and German populations (Pedersen et al., 1988; Schuster et al., 1990).  However, 
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to our knowledge no studies have been reported that attempt to identify the causative 
polymorphisms in the LDLR that functionally impact on plasma LDL-C.  Towards this goal, 
we report on the common allelic variations in the 3’ untranslated region (UTR) of the LDLR 
gene in humans, their functional impact on gene expression, and their association with 
variation in plasma lipid levels.   
The 3’UTR sequences have long been recognized as a regulatory region that is 
important for the appropriate expression of many genes (Conne et al., 2000; Chen et al., 
2006).  It contains cis-elements that affect the stability of transcripts, and/or influence the 
translation by interacting with the 5’ sequence of the transcripts.  For example, a stretch of 
AU-rich element (ARE) containing an AUUUA penta-nucleotide motif serves as a 
recognition site for specific proteins that increase the rate of poly A tail shortening and 
mRNA degradation.  The 3’UTR of the human LDLR gene includes three regions each 
containing an ARE, and Wilson et al. (1998) demonstrated that each element shortened the 
half-life of the reporter gene transcript by approximately 30% when introduced into the 
3’UTR of the β globin gene in a tissue culture based system.  Furthermore, we have 
previously shown that the removal of two of the three AREs in the 3’UTR of the LDLR gene 
leads to more stable transcripts and increased steady state levels of LDLR mRNA in mice 
(Knouff et al., 2001).  Therefore, common SNPs within or near these cis-elements may 
affect the binding of proteins to ARE or other control elements and hence alter gene 
expression in general human populations. 
 We describe here the identification of common genetic variations in the 3’UTR of 
the human LDLR gene.  We also demonstrate that these common variants have significant 
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association with plasma lipoprotein profiles in Caucasians enrolled in the Atherosclerosis 
Risk in Communities (ARIC) study. 
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Materials and Methods 
 
Identification of common polymorphisms in the mRNA LDLR 3’UTR 
 DNA was isolated from blood samples or fibroblasts from unrelated individuals, five 
Caucasians and nine African Americans (Maeda et al., 1983; Maeda, 1991).  The use of 
DNA in the current study was approved by the institutional review board of the University 
of North Carolina.  One kb DNA containing the 5’ of the 3’UTR of the human LDLR was 
PCR amplified from the genomic DNA using 1:1 mixture of Tgo DNA polymerase (Roche 
Applied Science, Penzberg Germany) and Taq DNA polymerase (New England Biolabs, 
Beverly, MA).  The forward and reverse primers, 5’-
TTTACGCGTACGTGGCGTGAACATCTGC-3’ and 5’-
TTTGGCGCGCCTCACGATCACGGCTTTGAAG-3’, contained additional nucleotides to 
generate MluI and AscI restriction sites at the 5’ and 3’ ends of the PCR products, 
respectively.  The PCR product was run on 0.8 % agarose gel to confirm the correct size, 
purified using QIAquick gel extraction kit (Qiagen Inc, Valencia, CA), and sequenced with 
each of the PCR primers.  Nucleotide sequences were compared to the LDLR gene sequence 
in the GenBank database (NC_000019).  PCR products from some individuals were cloned 
in pBluescript II vector (Stratagene, La Jolla, CA) to verify each haplotype seqeunce.  The 
MluI/AscI fragments with the three common haplotypes were isolated from these plasmids 
and cloned into the MluI site of the Hprt-hrGFPn 3’UTR test plasmid vector below. 
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ARIC study population and genotyping 
 
 The ARIC study is a prospective epidemiologic study whose main target is to 
investigate atherosclerotic vascular diseases and their risk factors (investigators 1989).  
Blood samples were drawn for the analysis of lipids and lipoproteins and DNA was 
extracted for genotyping (Brown et al., 1993).  The present study includes 10,602 
Caucasians and 3,497 African Americans.  Fasting plasma lipid data at the first cohort 
examination visit (1987-1989) was used for this analysis.  
 A total of 19,986 wells including negative and positive controls, non-blinded 
replicates, and blinded duplicates of 5% of the study samples were genotyped for C44857T 
and A44964G using TaqMan SNP allelic discrimination with ABI 7900HT Sequence 
Detection System (Applied Biosystems, Foster City, CA).  Primers and probes designed by 
Applied Biosystems were used (a reference number 4331183: Assay ID# C_2804304_10 / 
dbSNP# rs1433099 / Public location: Chr 19, Base: 11,103,658, and Assay 
ID#C_2804305_10 / dbSNP# rs2738466: Base: 11,103,765).  A 5 µl reaction mixture was 
used for PCR amplification that contains 3 ng of genomic DNA in 2.5 µl TaqMan Universal 
PCR master mix (Ranade et al., 2001).  Allelic fluorescence was measured using the 
7900HT and analyzed with SDS version 2.0, software (Perkin Elmer/ Applied Biosystems, 
Foster city, CA).  Replicate quality control samples were 100% concordance. 
 
Statistical analysis 
 
 All analyses were stratified by race and gender.  Haplotypes were estimated 
manually and by using the phase reconstruction method (PHASE 2.1), which assigned the 
most probable haplotype pair to each individual (Stephens, 2001; Stephens, 2003).  
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Deviations from Hardy-Weinberg equilibrium expectations were tested using a goodness-of-
fit test.  Multiple regression analysis was conducted utilizing SAS Version 8.1 making no 
assumptions about the inheritance pattern, applying a general model (two degree of freedom 
test, SAS Institute, Cary, NC).  Multivariable linear regression analysis was conducted to 
compare the mean estimated values of total cholesterol, LDL-C, HDL-C and LDL/HDL 
ratio in groups of individuals with different LDLR SNPs and diplotypes.  Analyses were 
carried out stratified by race and gender either adjusting for age, or fully adjusting for other 
well established lipid related covariates including age, field center, current drinker, current 
smoker, former smoker, use of medicine to lower cholesterol, use of lipid-lowering 
medications, medications that secondarily affect cholesterol, BMI and waist-to-hip ratio for 
men.  Additional adjustments for menopausal status and gonadal hormone use were made 
for women.  The mean adjusted lipid values within race and sex and stratified by LDLR 
genotype were calculated using ANOVA implemented in SAS Version 8.1. 
 
Reporter gene expression assay in mouse embryonic stem cells 
 
 The Hprt-hrGFPn 3’UTR test vector contains a reporter gene coding for humanized 
renilla Green Fluorescence Protein with a nuclear localizing sequence (hrGFPn, Stratagene, 
La Jolla,CA) driven by human β actin promoter that contained the first two non-coding 
exons (Kakoki et al., 2004).  The vector also contains two regions of the mouse Hprt gene 
sequence that allows homologous recombination in embryonic stem cells.  MluI/AscI 
fragments of the LDLR 3’UTR were inserted into a MluI site between the stop codon of 
hrGFPn and a poly A addition sequence of the Hprt-hrGFPn 3’UTR test vector.  3’UTR test 
plasmid DNA (10 µg) was linearized with PmeI and electroporated into mouse embryonic 
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stem cells, E14TG2a, that lack promoter and exon 1 and 2 of the Hprt gene.  Since 
homologous recombination restores the Hprt gene, only correctly targeted cells survive in a 
medium containing 4.8 µg/ml thymidine, 16 µg/ml hypoxanthine and 0.175 µg/ml 
aminopterin (HAT).  After selection for 10 days, drug resistant colonies were picked and 
expanded, and the fluorescence was measured with a Cytomation MoFlo cytometer having 
an argon laser for excitation at 488nm (Becton Dickinson, San Jose, CA).  10,000 events 
were collected for every analysis and the data was analyzed using summit 3.1 (DaKo 
cytomation, carpenteria, CA).  RNA was extracted from cells with Trizol reagent, and the 
mRNA of hrGFPn was measured by quantitative reverse transcription-PCR with the ABI 
7700 (Applied Biosystems, Foster City, CA;(Kim et al. 1990).  Forward and reverse primers 
for hrGFPn amplification were 5’- ATCCTGGTGTACCGCCTGAA-3’ and 5’- 
TGCTGGATGAAGTGGTACTC-3’, respectively.  The probe for hrGFPn detection was 5’-
Fam-CAAGTCCTTGTAGATCTCCTGGAGC-TAMARA-3’.  The β actin gene expression 
was used as an internal standard for each reaction. 
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Results 
 
 
SNPs and haplotypes of the LDLR 3’UTR sequence 
 
 We amplified 1.0 kb of DNA corresponding to the 5’ part of 3’UTR of the human 
LDLR gene by PCR in genomic DNA isolated from five unrelated Caucasians and nine 
unrelated African Americans.  Nucleotide sequence analyses of the PCR products confirmed 
polymorphisms at positions 44243, 44332, 44506, 44695, 44857, and 44964 within this 
region (Figure 2.1; SNP annotations: rs14158, rs3826810, rs2738464, rs2738465, 
rs1433099, and rs2738466, respectively).  One of the five Caucasians, C5, was homozygous 
for GGCGCA at the six SNP sites matching with the reference sequence (NC_000019).  We 
assigned this haplotype as Type I.  Individuals C1, C2, and C3 were heterozygous for the 
Type I and Type II carrying AGCACG at the six SNP sites.  An individual C4 was 
homozygous for GGCGTA, which we assigned as Type III.  These haplotypes were cloned 
and confirmed via direct sequencing.  Three additional haplotypes were found in African 
American individuals.  A haplotype with nucleotide of GGGGTA (Type IV) was in 
individuals AA3 and AA4, who were both heterozygous for this and a Type III.  Type V 
GGGGCA was seen in AA5 in combination with a Type III.  The G44332A polymorphism 
was rare with A being present in only one individual, AA1, who carry a sequence with 
GACACA (Type VI).  Again we established the haplotypes IV, V and VI by cloning of the 
individual DNA fragments followed by sequencing.  Haplotypes of the samples studied are 
summarized in Table 2.1. 
 The six haplotypes also account for the majority of nucleotide polymorphisms of the 
24 European Americans and 23 African Americans genotyped by Hinds et al (2005) and the 
PARC Study in Entrez SNP, (NCBI 
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http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=snp).  Thus the haplotypes of 20 of the 
24 European Americans are easily assigned into Types I, II or III.  The remaining three are 
heterozygous for Types II and IV, and one is heterozygous for Types III and VI.  Similarly, 
the haplotypes of 23 African Americans are readily assignable with haplotypes I through VI, 
except for two who are either heterozygous for Type I and IV or for Types III and V.  
Considering all available genotype data (Table 2.2), Types I, II and III are the most common 
haplotypes, occurring at frequencies of 0.45, 0.31 and 0.17 respectively in Caucasians 
(n=29) and 0.13, 0.13 and 0.38 respectively in African Americans (n=32).  The Type IV 
haplotype occurs at a frequency of 0.19 in African Americans.  The three common 
sequences Type I, II and III together account for 93% of the 3’UTR sequence of the LDLR 
gene in Caucasians, while they account for 64% of that in African Americans. 
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Figure 2.1.  3’UTR of the human LDLR gene.  A white box following the stop codon within 
the exon 18 is the 1kb region studied in the present work.  Positions of three ARE sequences 
are indicated by arrows.  Black boxes represent the Alu sequences in the remaining 2.5kb of 
the 3'UTR.  Locations of SNP sites and major and minor nucleotides are shown with the 
Gene bank dnSNP identification (ID) and nucleotide positions according to NC_000019 (nt. 
pos). 
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Table 2.1  SNPs in the 3’UTR of LDLR seen in individuals (AA=African American,  
C=Caucasian) 
ID 44243 44332 44506 44695 44857 44964 
Haplotypes 
(Predicted) 
AA1 G/G G/A C/C G/A C/T A/A III / VI* 
AA2 G/A G/G C/C G/A C/T A/G II / III 
AA3 G/G G/G C/G G/G T/T A/A III / IV* 
AA4 G/G G/G C/G G/G T/T A/A III / IV 
AA5 G/G G/G C/G G/G C/T A/A III / V* 
AA6 G/G G/G C/C G/G T/T A/A III / III 
AA7 G/A G/G C/C G/A C/T A/G II / III 
AA8 G/A G/G C/C G/A C/C A/G  I / II 
AA9 G/G G/G C/C G/G T/T A/A III / III 
C1 G/A G/G C/C G/A C/C A/G  I / II* 
C2 G/A G/G C/C G/A C/C A/G I / II 
C3 G/A G/G C/C G/A C/C A/G  I / II 
C4 G/G G/G C/C G/G T/T A/A III / III* 
C5 G/G G/G C/C G/G C/C A/A I / I* 
          *Established by cloning and sequencing. 
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Genotype assignment and frequencies in ARIC subjects 
 
 We searched in NCBI genome databank the homologous 3’UTR sequence of the 
LDLR gene in other primates.  The nucleotides at the six SNP sites are GGCGTA in Colobus 
(AC150433), GGCGTG in Baboons (AC140974), GGCGTG in Rhesus (CN642890), and 
GGCGCG in Chimpanzees (NW_119754).  While the nucleotides at the six SNP sites of the 
most common haplotype (GGCGTA) in African Americans were shared with those in the 
Colobus monkey, other combinations including the most common haplotype (GGCGCA) 
were not seen in these primate species.  The numbers of sequence entry for each of the 
different primate species available from the NCBI databank were limited.  However, when 
multiple sequences were available, we did not find intra-species differences at these sites, 
although we were not able to find whether these sequences were all from a single individual 
or from multiple different individuals.   
Since parallel occurrence of the same nucleotide substitutions during the primate 
evolution can be considered rare, the polymorphisms at positions 44857 and 44964 are 
likely of ancient origins.  In addition, the combinations of these two SNPs can predict the 
haplotypes, at least in the majority of Caucasians.  Consequently, we chose to genotype 
these two SNPs (rs1533099 and rs2738466 respectively) in the large ARIC study.  The 
distributions of C44857T and A44964G diplotypes were in Hardy-Weinberg equilibrium for 
both races (p>0.05).  The relative frequencies of C44857T and A44964G were significantly 
different between African Americans and Caucasians (Table 2.3).  The frequency of C at 
44857 was higher in Caucasians (0.73) compared to the African Americans (0.46).  The 
Caucasians had a lower frequency of A at position 44964 than did the African Americans 
(0.74 vs 0.83).  Allelic frequencies of C44857T, A44964G and their combinations in the 
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ARIC subjects and in the individuals used to estimate the frequencies of 3’UTR hapotypes 
(Table 2.2 and 2.3) were not significantly different (Fisher’s exact test).    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 44 
 
 
 
 
 
 
Table 2.2  Frequencies of the 3’UTR haplotypes of the human LDLR gene 
Haplotype Caucasians African Americans 
 This study  
n=10 
Perlegen 
n=48 
Total  
% 
This study 
n=18 
Perlegen 
n=46* 
Total 
% 
I GGCGCA 5 21 45% 1 7 13% 
II AGCACG 3 15 31% 3 5 13% 
III GGCGTA 2 8 17% 10 14 38% 
IV GGGGTA 0 3 5% 2 10 19% 
V GGGGCA 0 0 0% 1 5 9% 
VI GACACA 0 1 2% 1 5 9% 
• Two individuals were heterozygous for either Type I/IV or III/V.  Chromosome 
numbers.were counted. 
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 Three combinations of these two SNPs C44857-A44964 (CA: corresponding to 
haplotypes I, V and VI), C44857-G44964 (CG: corresponding to haplotype II) and T44857-
A44964 (TA: corresponding to haplotypes III and IV) predicted the majority of the 
haplotypes in the ARIC population (Table 2.2).  However, two of 10,602 Caucasians were 
genotyped as carrying T/T at 44857 and G/G at 44964; twelve individuals were C/T at 44857 
but G/G at 44964.  This suggests that TG is a minor haplotype present at a low frequency in 
this population.  Thus, while likelihood-based haplotype inference assigned the 1,465 
individuals who are doubly heterozygous for C44857T and A44964G as CG/TA, a fraction 
of them (less than 20) may be CA/TG.  Of 3,497 African Americans, the inferred haplotype 
combinations of TG/TG, CG/TG and TA/TG were seen 2, 4, and 43 times respectively.  Thus 
the TG haplotype is present at a higher frequency in African Americans than in Caucasians, 
and approximately 5-10% of those being assigned as CG/TA may be CA/TG.  Individuals 
with TG/TG, CG/TG and TA/TG were grouped as rare. 
The inferred diplotype frequencies differed significantly between Caucasians and 
African Americans in this study.  The Caucasian group had a higher frequency than African 
Americans for CA/CA (22.18% vs. 9.09%), CA/CG (25.31% vs 9.78%) and CG/CG (6.21% 
vs 2.60%), while the African American group had higher frequencies than Caucasians in 
CA/TA (31.20% vs 24.7%), CG/TA (18.19% vs 13.82%) and TA/TA (27.80% vs 7.67%).  
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Table 2.3.  Frequencies of C44857T and A44964G, and of combined alleles in 
ARIC study population 
  Caucasian African American 
  Men Women Men Women 
  N=4,967 N=5,635 N=1,316 N=2,181 
C44857T 
 C/C 2,628 (52.9%) 3,065 (54.4%) 296 (22.5%) 455 (20.8%) 
 C/T 1,932 (39.0%) 2,155 (38.2%) 661 (50.2%) 1,069 (49.0%) 
 T/T 407 (8.2%) 415 (7.4%) 359 (27.3%) 657 (30.1%) 
A44964G 
 A/A 2,749 (55.3%) 3,035 (53.8%) 881 (66.9%) 1,500 (68.8%) 
 A/G 1,890 (38.1%) 2,265 (40.2%) 406 (30.8%) 615 (28.2%) 
 G/G 328 (6.6%) 335 (5.9%) 29 (2.2%) 66 (3.0%) 
Alleles (C44857T - A44964G) 
 C-T 46.8% 47.6% 31.7% 28.9% 
 C-G 25.6% 26.0% 17.6% 16.6% 
 T-A 27.5% 26.4% 51.7% 53.9% 
 T-G 0.05% 0.08% 0.6% 0.7% 
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Inferred haplotypes of LDLR 3’UTR and lipid profiles in ARIC subjects. 
 
 Of the 15,792 total subjects who agreed to participate in the ARIC study, 1,693 were 
excluded because their lipid and lipoprotein data at their first visit (baseline) were not 
available or because their plasma total cholesterol levels were four standard deviations from 
the mean, or their informed consent precluded the use of their DNA.  The study population 
characteristics are presented in Supplementary Table 2.7, subdivided by race and gender. 
 Multiple regression analysis was conducted to compare the mean estimated values of 
total cholesterol, LDL-C, HDL-C and LDL/HDL ratio in groups of individuals with 
different LDLR genotypes (Table 2 4).  Fully adjusted mean LDL-C levels were 7 mg/dl and 
4 mg/dl higher in C/C (44857) homozygous Caucasian males and females than T/T (44857) 
homozygous (P=0.0016 and P<0.06 respectively).  LDL-C levels in African American 
females were 3 mg/dl higher in C/C homozygous compared to T/T homozygotes (P=0.43).  
In contrast, no effects of C44857T on LDL-C levels were detected in African American 
males.  The A44965G polymorphism had no effects on the lipid profiles in either 
population.  Analysis carried out adjusting only for age showed no differences in mean 
values and significance from fully adjusted analysis (not shown). 
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Table 2.4.  Adjusted plasma lipid parameters in ARIC subjects according to genotypes of C44857T and 
A44965G 
SNP C44857T P* A44965G P* 
 C/C C/T T/T  A/A A/G G/G  
C, Men N=2,628 N=1,932 N=4,07  N=2,749 N=1,890 N=328  
LDL/HDLª 3.54±0.02 3.46±0.03 3.34±0.06 0.005 3.50±0.02 3.49±0.03 3.49±0.07 0.93 
HDL
b
 42±1 43±1 42±1 0.080 43±1 43±1 42±1 0.36 
LDL
c
 141±1 140±1 134±2 0.003 140±1 139±1 140±1 0.77 
TC
d
 211±1 211±1 205±2 0.006 211±1 210±1 210±2 0.88 
C, Women N=3,065 N=2,155 N=415  N=3,035 N=2,265 N=335  
LDL/HDLª 2.61±0.02 2.58±0.02 2.51±0.05 0.17 2.59±0.02 2.57±0.02 2.67±0.06 0.31 
HDL
b
 57±1 58±1 57±1 0.61 58±1 58±1 58±1 0.73 
LDL
c
 135±1 136±1 131±2 0.07 136±1 134±1 138±2 0.22 
TC
d
 218±1 218±1 214±2 0.15 218±1 217±1 221±2 0.36 
AA, Men N=296 N=661 N=359  N=881 N=406 N=29  
LDL/HDLª 3.01±0.07 2.9911±0.05 3.0915±0.07 0.47 3.07±0.04 2.92±0.06 2.97±1.00 0.13 
HDL
b
 51±1 51±1 49±1 0.07 50±1 51±1 51±3 0.26 
LDL
c
 137±2 138±2 137±2 0.91 139±1 137±2 126±8 0.19 
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TC
d
 212±3 212±2 209±2 0.61 212±2 210±2 205±8 0.66 
AA,Women N=455 N=1069 N=657  N=1500 N=615 N=66  
LDL/HDLª 2.66±0.05 2.53±0.04 2.62±0.05 0.08 2.59±0.03 2.58±0.05 2.57±0.14 0.99 
HDL
b
 58 ±1 58±1 57 ±1 0.43 57±1 58 ±1 61±2. 0.27 
LDL
c
 141±2. 135±1 138±2 0.04 137±1 137±2 140±5 0.80 
TC
d
 221±2 214±1 216±2 0.03 215±1 217±2 222±6 0.35 
 30 
We next compared the mean value of each lipoprotein variable of the individuals 
with inferred C44857T - A44965G diplotypes against the mean of the given variable of all 
other individuals who did not have the inferred diplotype (Table 2.5).  The most striking 
associations between the diplotypes and plasma cholesterol levels were observed in 
Caucasian men.  Caucasian men with TA/TA had 6.06 mg/dl lower total cholesterol (P= 
0.002), 6.10 mg/dl lower LDL-C (P= 0.001) and lower LDL/HDL ratio (P= 0.01) than those 
with other diplotypes.  Conversely, men with the CA/CA had 2.46 mg/dl higher LDL-C 
(P=0.04) and 0.91 mg/dl lower HDL-C (P= 0.02) than those with other diplotypes 
respectively.  The estimated mean of LDL/HDL ratio was significantly higher in men with 
the CA/CA (P=0.001).  Caucasian women with the TA/TA diplotypes demonstrated a similar 
pattern of results with 4.07 mg/dl lower total cholesterol (P= 0.04), and 4.63 mg/dl lower 
LDL-C (P=0.01) when compared to women with all other diplotypes.  The cholesterol 
raising effects of CA/CA diplotypes were not observed in the Caucasian female ARIC 
participants.  Inferred diplotypes were not associated with plasma lipid profiles in African 
American men except that TA/TA diplotypes had significantly lower (2.12 mg/dl, P=0.03) 
HDL-C levels when compared to all other African American men. No diplotype effects were 
noted in the African American women.  We also compared the mean value of each 
lipoprotein variable of the individuals with inferred C44857T- A44965G diplotypes against 
the mean of the most common diplotype of each group (CA/CG in Caucasians and CA/TA 
in African Americans) and results were very similar. (Supplementary Table 2.8).   
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Table 2.5.  Diplotype frequencies and estimated differences in lipoprotein cholesterol 
levels in individuals with a given diplotype compared to those with other diplotypes. 
Diplotypes Frequency TC
a
 LDL-C
 b
 HDL-C
c
 LDL/HDL
d
 
 N       (%) Estimate (P*) Estimate (P*) Estimate (P*) Estimate (P*) 
Caucasian Men     
CA/CA 1,104 (22.2%) 1.85 (0.15) 
CA/CG 1,196 (24.1%) 0.29 (0.82) 
CA/TA 1,243 (25.0%) 1.37 (0.27) 
CG/CG 328 (6.6%) 
CG/TA 689 (13.9%) 
TA/TA 402 (8.1%) 
-0.49 (0.82) 
-1.08 (0.48) 
-6.06 (0.002) 
2.46 (0.04) 
0.15 (0.89) 
1.06 (0.36) 
-0.13 (0.94) 
-1.46 (0.32) 
-6.10 (0.001) 
-0.91 (0.02) 
0.28 (0.46) 
0.99 (0.009) 
-0.93 (0.15) 
-0.05 (0.90) 
-0.15 (0.80) 
0.14 (0.001) 
0.007 (0.87) 
-0.04 (0.27) 
-0.003 (0.96) 
-0.03 (0.53) 
-0.16 (0.01) 
Caucasian Women 
CA/CA 1,248 (22.2%) 
CA/CG 1,487 (26.4%) 
CA/TA 1,376 (24.4%) 
CG/CG 330 (5.9%) 
CG/TA 776 (13.8%) 
TA/TA 411 (7.3%) 
0.53 (0.67) 
-0.50 (0.67) 
1.48 (0.23) 
2.96 (0.19) 
-1.28 (0.41) 
-4.07 (0.04) 
0.56 (0.64) 
-0.45 (0.69) 
2.08 (0.07) 
2.80 (0.20) 
-2.10 (0.15) 
-4.63 (0.01) 
-0.15 (0.74) 
-0.32 (0.47) 
-0.20 (0.66) 
0.15 (0.85) 
1.22 (0.03) 
-0.14 (0.85) 
0.01 (0.67) 
0.02 (0.51) 
0.03 (0.37) 
0.07 (0.25) 
-0.10 (0.02) 
-0.09 (0.10) 
African American Men 
CA/CA 124 (9.4%) 
CA/CG 145 (11.0%) 
CA/TA 413 (31.4%) 
CG/  CG 27 (2.1%) 
4.64 (0.26) 
-1.36 (0.73) 
2.31 (0.38) 
-5.09 (0.55) 
4.90 (0.21) 
-3.52 (0.34) 
1.35 (0.59) 
-11.24 (0.17) 
-0.57 (0.70) 
2.99 (0.03) 
0.54 (0.57) 
-0.98 (0.75) 
0.14 (0.21) 
-0.16 (0.13) 
0.001 (0.99) 
-0.02 (0.94) 
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CG/TA 246 (18.7%) 
TA/TA 344 (26.2%) 
-0.67 (0.83) 
-2.56 (0.36) 
0.02 (0.99) 
-0.18 (0.94) 
0.54 (0.63) 
-2.12 (0.03) 
-0.10 (0.27) 
0.10 (0.19) 
African American Women 
CA/CA 194 (8.9%) 
CA/CG 197 (9.0%) 
CA/TA 678 (31.1%) 
CG/CG 64 (2.9%) 
CG/TA 390 (17.9%) 
TA/TA 628 (28.8%) 
0.94 (0.78) 
8.11 (0.01) 
-3.26 (0.12) 
7.21 (0.21) 
-2.18 (0.39) 
0.33 (0.87) 
1.74 (0.59) 
7.04 (0.03) 
-2.82 (0.16) 
3.87 (0.48) 
-3.07 (0.21) 
1.16 (0.57) 
-0.68 (0.60) 
0.62 (0.62) 
0.03 (0.97) 
2.61 (0.22) 
0.94 (0.32) 
-0.85 (0.29) 
0.05 (0.52) 
0.13 (0.16) 
-0.07 (0.18) 
0.02 (0.91) 
-0.08 (0.22) 
0.06 (0.29) 
 
*P value is from a test comparing the mean adjusted estimate of the lipid value in 
individuals with a given diplotype compared to all others who do not have the diplotype of 
interest. The p value from an overall test comparing the unadjusted estimate of the lipid 
value in individuals with a given diplotype compared to all others who do not have the 
diplotype of interest are similar to the adjusted (not shown). 
a,
 Values were adjusted for age, field center, current smoker, use of medicine to lower 
cholesterol.  In addition, values were adjusted for former smoker and waist to hip ratio for 
men, and for medicine that secondarily affects cholesterol, menopausal status, current 
hormone usage, BMI, and waist-to-hip ratio for women.  
b,
 Values were adjusted for age, field center, current smoker, use of medicine to lower 
cholesterol.  In addition, values were adjusted for former smoker and leisure physical 
activity index for men, and for menopausal status, current hormone usage, interaction 
between menopause and hormone usage, and waist-to-hip ratio for women.  
c,
 Values were adjusted for age, current smoker, use of medicine to lower cholesterol, and 
sport physical activity index.  In addition, values were adjusted for field center and former 
smoke for men, and for current drinker, menopausal status, current hormone usage, 
interaction between menopause and hormone usage, BMI and waist-to-hip ratio for women. 
d,
 Values were adjusted to age, current smoker, current drinker, use of medicine to lower 
cholesterol, use of medicine that secondarily affects cholesterol, BMI, and waist-to-hip ratio.  
In addition, values were adjusted for field center for men, and for former smoker, 
menopausal status, current hormone usage, interaction between menopause and hormone 
usage for women. 
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Effects of LDLR 3’UTR sequences on gene expression 
 
To test whether the common sequences Type I (GGCGCA), Type II (AGCACG), and 
Type III (GGCGTA) in the 3’UTR of LDLR affect the level of gene expression, we used a 
Hprt-hrGFPn-3’UTR test system (Kakoki et al., 2004).  Since Type I, type II, and type III 
did not show any associations with lipid parametrs in African Americans, we then studied 
the expression of additional reporter constructs containing type IV (GGGGTA) and type V 
(GGGGCA) sequences which are more common in African Americans.  The five plasmid 
constructs, each carrying the 3’UTR sequences of Type I, II, III, IV and V immediately 3’ to 
the stop codon of the hrGFPn reporter gene, were introduced into mouse embryonic stem 
(ES) cells with a deletion in the Hprt gene.  Homologous recombination between the 
reporter constructs with ES cell genome inserts a single copy of the reporter gene into the 
Hprt locus and simultaneously restores the Hprt gene function and allows the cells to 
survive in a medium containing thymidine, hypoxanthine and aminopterin (Figure 2.2).  The 
experiment was repeated four times and the average of the median intensity of GFP 
Fluorescence of 10,000 cells collected by flow cytometer per experiment was compared.  
The results demonstrate that the hrGFPn mRNA levels measured by quantitative reverse 
transcription-PCR showing that mRNA levels in the cells with Type I, II, III, IV,and V 
sequences was not statistically significant.  Also, the GFP fluorescent intensity correlated 
well with the hrGFPn mRNA levels. These data demonstrate that the common 
polymorphisms in the 3’UTR of the human LDLR gene do not affect expression of the 
reporter gene in a tissue culture system (Table 2.6).   
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Figure 2.2.  Effects of the 3’UTR haplotypes I, II III IV and V on reporter gene expression, 
3’UTR test system.  The target Hprt locus (top line) in the mouse ES cells, E14TG2a, has a 
deletion of DNA including promoter and exons 1 and 2 as indicated by the parenthesis.  
Black and white boxes indicate coding and non-coding exons 3 through 9.  The reporter 
gene construct (middle line) contains a human β actin promoter, the hrGFPn coding 
sequence, and 5’ and 3’ regions of homology arms (thick horizontal lines).  Each of the 1kb 
DNA from the human LDLR 3'UTR was inserted into the MluI site just 3’ to the stop codon.  
Homologous recombination between the two arms of homologies (large Xs) restores the 
Hprt gene and inserts a single copy of the reporter gene (bottom line).   
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               Table 2. 6.  Effects of the 3’UTR haplotypes I, II, III, VI and V  
               on reporter gene expression 
 
 
 
 
 
Haplotypes are nuclerotide positions 44243, 44332, 44506, 44695, 44857, and 
44964 (rs14158, rs3826810, rs2738464, rs2738465, rs1433099, and rs2738466). 
hrGFPn fluorescence activity.  The fluorescence of 10,000 cells was measured in each 
experiment and the activity is expressed relative to the mean fluorescence of Type I 
haplotype as 100%.  hrGFP mRNA levels.  RNA was isolated from HAT resistant cells and 
the amount of hrGFP mRNA relative to β actin was determined by RT-PCR and expressed 
relative to the mean of type I haplotype as 100 %. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Reporter Gene Expression 
Haplotypes 
Fluorescence mRNA 
I GGCGCA 100±13 100±6 
II AGCACG 106±13 133±22 
III GGCGTA 102±14 139±15 
IV GGGGTA 108±13 121±13 
V GGGGCA 109±13 133±17 
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Discussion 
 
 In this study we demonstrated that, in a tissue culture based reporter gene assay, 
common polymorphisms in the 3’UTR sequence of the human LDLR gene do not influence 
the gene expression at the mRNA level.  We also demonstrated that the common haplotypes 
in the 3’UTR contribute to inter-individual variations in plasma total cholesterol, LDL-C, 
HDL-C, and LDL/HDL ratio in Caucasians. 
 Since the LDLR plays an important role in plasma lipoprotein homeostasis, genetic 
variations in the LDLR gene could contribute to inter-individual differences in lipoprotein 
cholesterol levels in the general population.  In testing this hypothesis, we focused on 
common variations in the 3’UTR because it is considered a regulatory region that is 
important for the appropriate expression of many genes by affecting the mRNA degradation 
and stability.  Within the 5’ portion of the 3’UTR of the human LDLR gene there are two 
stretches of DNA that are conserved between rodents and humans in the LDLR gene, and 
each of these stretches contains AUUUA motifs (underlined in Supplementary Figure 1).  
Although none of the SNP sites overlap directly with the AUUUA sequence, two of the SNP 
sites, 44332 and 44857, are located within these homology blocks.  As seen in table 6, of the 
five most common polymorphisms in the 3’UTR of the human LDLR gene, the expression 
of the reporter gene in a tissue culture system was not statistically different among the five 
types. 
Our analysis also detected an association between 3’UTR polymorphisms and 
variation in the lipoprotein cholesterol levels in the general population.  Although the 
proportions of the sample variance explained by the two SNPs are small (see Supplemental 
Table 2.2 for comparison of the size of the effects with some other factors), our data  
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suggests that some of the genetic variations in the 3’UTR are important determinants of 
coronary heart disease risk in Caucasians in the ARIC study.  Thus Caucasian men 
homozygous for the CA/CA diplotype had a significantly higher LDL-C and significant 
lower HDL-C levels.  As a result, they also had a 4.5% higher LDL/HDL ratio, an 
established risk factor for CHD (Panagiotakos et al., 2003).  Conversely, Caucasian men that 
were homozygous for the TA/TA diplotype had significantly lower total cholesterol and 
LDL-C, and a 5.3% lower LDL/HDL ratio.  The effects of these LDLR polymorphisms in 
Caucasian women were generally smaller than those detected in men.  Particularly 
noteworthy is the absence of the LDL-C increasing effect of the CA/CA genotype in women, 
while the LDL-C lowering effect of TA/TA genotype was still significant. 
 To our knowledge, there have been no previous reports of any positive or negative 
associations between LDLR polymorphisms and plasma lipid profiles in African American 
population.  In our study, we did not detect any association between the 3’UTR diplotypes 
and the lipid profiles in the African American ARIC population. Importantly, however, we 
note that our present study has limited haplotype assignments for African American 
individuals.  Genotyping at the two SNP sites can reasonably identify the most common 
3’UTR haplotypes, GGCGCA, AGCACG and GGCGTA, which account for 93% of the 
3’UTR sequences of the LDLR gene in Caucasians.  In contrast, these three haplotypes 
account for only 64% of the haplotypes in African Americans.  In addition, the two SNP 
sites that we chose to genotype did not distinguish GGGGCA and GACACA from GGCGCA, 
or GGGGTA from GGCGTA.  Thus, only 43% of the CA haplotype is GGCGCA in African 
Americans, and 66% of the TA haplotype is GGCGTA.  This limitation in haplotype 
assignment is likely to have reduced the power of detecting association between the 
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diplotypes and plasma lipids in African Americans.  The haplotype GGGGTA is more 
prevalent in African Americans (19%) than in Caucasians (5%), and the haplotype 
GGGGCA is only seen in African Americans (9%).  These two haplotypes share the G allele 
at 44506.  The effect of the G allele at 44506 on the expression of the LDLR gene in vitro 
was not different from other types. 
 Another important consideration is the effect of a long-range linkage disequilibrium 
observed in this region of chromosome in Caucasians.  Previous studies (Knoblauch et al., 
2004) estimated the presence of 22 haplotypes from 7 SNPs in 32 kb of the DNA, spanning 
intron 1 to the 3’UTR among a total of 1054 normolipidemic subjects from 218 families in 
the German population: three major haplotypes accounting for 71 % of the chromosomes.  
Their finding that the long range LDLR haplotypes contribute to the genetic variance of LDL 
(5%), HDL (6%) and LDL/HDL ratio (2%) is thus consistent with the significant association 
of the 3’UTR haplotypes with these parameters in Caucasians we observed in the current 
study.  In addition, the AvaII site in exon 13 and PvuII site in intron 15, the presence and 
absence respectively of which have been reported previously to be associated with increased 
LDL-C levels in an Italian population, Hispanic and non-Hispanics, and Brazilian whites, 
are also in linkage disequilibrium with the 3’UTR polymorphisms (Ahn et al., 1994; 
Schuster et al; 1990, Knoblauch et al., 2004; Salazar et al., 2000; Humphries et al., 1991).  
This long range linkage disequilibrium demonstrated that the real causative 
polymorphism(s) which affect the plasma lipid parameters are not the 3’UTR sequence per 
se but others that are in linkage disequilibrium with them. 
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 The primary finding of this study is that the GGCGCA haplotype is associated with 
higher levels of total and LDL-C in Caucasians, whereas the GGCGTA haplotype is 
associated with lower levels of cholesterol levels. 
 In conclusion, our findings show that common genetic variation in the 3’UTR of the 
LDLR are significantly associated with plasma lipid levels in normolipidic Caucasian 
subjects.  Further studies are necessary to elucidate the mechanism underlying this 
association. 
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Supplemental Materials 
 
ARIC Population :  The present study includes 10,602 Caucasians and 3,497 African 
Americans.  The study population characteristics presented in Supplementary Table 1, show 
that current alcohol consumption was reported more frequently in Caucasians than in 
African Americans, while more male African American participants reported that they were 
current smokers in comparison to Caucasian males.  A larger proportion of African 
American women reported that they had reached menopausal status in comparison to 
Caucasian women, whereas more Caucasian women reported both previous and current 
gonadal hormone use in comparison to African American women.  Mean total cholesterol, 
and HDL-C concentrations in women of both races were higher than those of the men, but 
Caucasian men had lower HDL-C values in comparison to African American men.  There 
were no significant differences in the LDL-C levels between African American men and 
women, but Caucasian men had slightly higher LDL-C concentrations in comparison to 
Caucasian women.  The analyses were carried out stratified by race and gender either 
adjusting for age, or fully adjusting for age, field center, current alcohol consumption, 
current smoking, former smoking, use of lipid-lowering medications, use of medications that 
secondarily affect cholesterol, body mass index (BMI) and waist-to-hip ratio for men.  
Additional adjustments for menopausal status and gonadal hormone use were made for 
women. 
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Supplementary Table2.7.  Basic characteristics of ARIC population. 
  Caucasian African American 
  Men Women Men Women 
Drinking status 
 Current drinker 3,419 (69.0%) 3,411 (60.6%) 652 (49.9%) 453 (21.0%) 
 Former drinker 1,033 (20.9) 805 (14.3%) 359 (27.5%) 419 (19.4) 
 Current smoker 1,182 (23.8) 1,393 (24.7%) 494 (37.6%) 527 (24.2%) 
 Former smoker 2,397 (48.3) 1,388 (24.7%) 441 (33.5%) 378 (17.4%) 
Cholesterol lowering medication 
 Primary 183 (3.7) 184 (3.3%) 17 (1.3%) 32 (1.5%) 
 Secondary 1,039 (21.1%) 1,312 (23.4%) 331 (25.7%) 764 (35.4%) 
Menopausal status 
 Menopausal N/A 3,452 (61.5%) N/A 1,395 (64.4%) 
Hormonal use 
 Current hormone 
usage 
N/A 1,165 (21.3%) N/A 302 (14.6%) 
 Menopause and 
current hormone 
usage  
N/A 777 (14.2%) N/A 239 (11.6%) 
Centers 
 Forsyth County, 
NC 
1,483 (29.8%) 1,737 (30.8%) 162 (12.3%) 238 (10.9%) 
 Washington, MD 
and Jackson, MS 
1,756 (35.4%) 1,916 (34.0%) 1,154 (87.7%) 1,943 
(89.1%) 
 Minneapolis, MN 1,728 (34.8%) 1,982 (36.2%) 0 0 
Continuous Covariates 
 Age 55±5.7 54±5.7 54±6.0 53±5.7 
 BMI 27.43±4.00 26.61±5.49 27.63±4.83 30.72±6.50 
 Waist to hip ratio 0.97±0.05 0.89±0.08 0.94±0.06 0.90±0.08 
 Sport physical 
activity index 
2.67±0.82 2.42±0.77 2.26±0.74 2.10±0.65 
 Leisure physical 
activity index 
2.42±0.52 2.50±0.54 2.07±0.57 2.07±0.58 
Lipid values 
 TC (mg/dl) 211±38 218±41 211±44 217±44 
 LDL-C (mg/dl) 140±35 135±40 138±41 137±42 
 HDLC (mg/dl) 43±12 58±17 50±17 58±17 
 LDL/HDL 3.49±1 2.60±1 3.02±1 2.61±1 
Values are mean±SD.  N/A, not applicable.  BMI, body mass index; TC, total cholesterol.
  43 
 
Supplementary Table 2.8.  Diplotype frequencies and the mean adjusted estimate of 
cholesterol in individuals with a given diplotype compared to the most common diplotype. 
Diplotypes Frequency TC
a
 LDL-C
 b
 HDL-C
c
 LDL/HDL
d
 
 N       (%) Estimate (P*) Estimate (P*) Estimate (P*) Estimate (P*) 
Caucasian Men 
CA/CA 1,104 (22.2%) 0.85 (0.59) 
CA/CG 1,196 (24.1%) 1.0 (ref) 
CA/TA 1,243 (25.0%) 0.13 (0.93) 
CG/CG 328 (6.6%) 
CG/TA 689 (13.9%) 
TA/TA 402 (8.1%) 
-1.12 (0.64) 
-1.66 (0.37) 
-6.48 (0.003) 
1.64 (0.27) 
1.0 (ref) 
0.25 (0.86) 
-0.47 (0.83) 
-1.51 (0.38) 
-6.14 (0.003) 
-0.98 (0.06) 
1.0 (ref) 
0.98 (0.049) 
-1.09 (0.15) 
- 0.09 (0.88) 
-0.58 (0.42) 
0.09 (0.09) 
1.0 (ref) 
-0.09 (0.08) 
-0.01 (0.86) 
-0.06(0.36) 
-0.15 
(0.047) 
Caucasian Women 
CA/CA 1,248 (22.2%) 
CA/CG 1,487 (26.4%) 
CA/TA 1,376 (24.4%) 
CG/CG 330 (5.9%) 
CG/TA 776 (13.8%) 
TA/TA 411 (7.3%) 
0.10 (0.95) 
1.0 (ref) 
1.24 (0.41) 
1.65 (0.50) 
-1.55 (0.38) 
-3.90  (0.08) 
0.37 (0.80) 
1.0 (ref) 
1.62 (0.26) 
1.68 (0.47) 
-2.25 (0.18) 
-4.68 (0.03) 
0.05 (0.94) 
1.0 (ref) 
0.51 (0.42) 
0.62 (0.55) 
1.96 (0.01) 
0.74 (0.43) 
-0.01 (0.79) 
1.0 (ref) 
0.02 (0.68) 
0.01 (0.92) 
-0.13 (0.02) 
-0.14 (0.04) 
African American Men 
CA/CA 124 (9.4%) 
CA/CG 145 (11.0%) 
CA/TA 413 (31.4%) 
CG/CG 27 (2.1%) 
CG/TA 246 (18.7%) 
TA/TA 344 (26.2%) 
2.62 (0.56) 
-1.61 (0.71) 
1.0 (ref) 
-6.26 (0.47) 
-1.10 (0.76) 
-2.76 (0.39) 
3.28 (0.45) 
-1.91 (0.64) 
1.0 (ref) 
-10.99 (0.19) 
0.55 (0.87) 
-0.51 (0.87) 
-0.74 (0.67) 
3.25 (0.05) 
1.0 (ref) 
-0.97 (0.77) 
0.54 (0.70) 
-1.83 (0.14) 
0.12 (0.36) 
-0.16 (0.22) 
1.0 (ref) 
-0.03 (0.91) 
-0.06 (0.55) 
0.09 (0.41) 
African American Women 
CA/CA 194 (8.9%) 
CA/CG 197 (9.0%) 
CA/TA 678 (31.1%) 
CG/CG 64 (2.9%) 
CG/TA 390 (17.9%) 
TA/TA 628 (28.8%) 
4.42 (0.22) 
11.45 (0.001) 
1.0 (ref) 
11.12 (0.05) 
2.41 (0.39) 
3.59 (0.14) 
4.20 (0.23) 
9.16 (0.01) 
1.0 (ref) 
8.33 (0.13) 
0.77 (0.78) 
3.47 (0.14) 
-0.48 (0.74) 
0.13 (0.93) 
1.0 (ref) 
2.60 (0.25) 
0.50 (0.66) 
-1.10 (0.26) 
0.12 (0.21) 
0.19(0.04) 
1.0 (ref) 
0.12 (0.44) 
0.01(0.88) 
0.12 (0.07) 
 
**P value is from a test comparing the mean adjusted estimate of the lipid value in 
individuals with a given diplotype compared to the reference (individuals with CA/CG in 
Caucasians and with CA/TA in African Americans) 
a,
 Values were adjusted for age, field center, current smoker, use of medicine to lower 
cholesterol.  In addition, values were adjusted for former smoker and waist to hip ratio for 
men, and for medicine that secondarily affects cholesterol, menopausal status, current 
hormone usage, BMI, and waist-to-hip ratio for women.  
b,
 Values were adjusted for age, field center, current smoker, use of medicine to lower 
cholesterol.  In addition, values were adjusted for former smoker and leisure physical 
activity index for men, and for menopausal status, current hormone usage, interaction 
between menopause and hormone usage, and waist-to-hip ratio for women.  
  44 
c,
 Values were adjusted for age, current smoker, use of medicine to lower cholesterol, and 
sport physical activity index.  In addition, values were adjusted for field center and former 
smoke for men, and for current drinker, menopausal status, current hormone usage, 
interaction between menopause and hormone usage, BMI and waist-to-hip ratio for women. 
d,
 Values were adjusted to age, current smoker, current drinker, use of medicine to lower 
cholesterol, use of medicine that secondarily affects cholesterol, BMI, and waist-to-hip ratio.  
In addition, values were adjusted for field center for men, and for former smoker, 
menopausal status, current hormone usage, interaction between menopause and hormone 
usage for women.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  45 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Table 2.9.  Estimate of the proportion of the sample variance explained 
by C44857T, A44965G, age, smoking and total covariates 
 C44857T A44965G Age Smoking Total 
Covariates 
C, Men      
  LDL/HDL ratio 0.28% 0.001% 0.002% 1.22% 8.38% 
  HDL (mg/dl) 0.21% 0.05% 0.22% 0.69% 13.3% 
  LDL (mg/dl) 0.27% 0.01% 0.17% 0.27% 1.44% 
  TC (mg/dl) 0.23% 0.002% 0.3% 0.35% 1.96% 
C, Women      
  LDL/HDL 
ratio 
0.09% 0.02% 1.33% 2.35% 22.3% 
  HDL (mg/dl) 0.07% 0.01% 0.001% 1.79% 25.9% 
  LDL (mg/dl) 0.08% 0.04% 4.12% 0.55% 11.6% 
  TC (mg/dl) 0.05% 0.03% 6.14% 0.12% 10.5% 
AA, Men      
  LDL/HDL 
ratio 
0.12% 0.31% 0.002% 0.82% 12.2% 
  HDL (mg/dl) 0.43% 0.39% 0.02% 0.14% 16.2% 
  LDL (mg/dl) 0.01% 0.20% 0.10% 3.18% 3.66% 
  TC (mg/dl) 0.07% 0.05% 0.09% 2.31.% 2.79% 
AA,Women      
  LDL/HDL 
ratio 
0.34% 0.01% 1.51% 0.79% 5.3% 
  HDL (mg/dl) 0.17% 0.10% 0.07% 1.33% 15.3% 
  LDL (mg/dl) 0.4% 0.11% 2.63% 0.001% 6.3% 
  TC (mg/dl) 0.46% 0.25% 3.01% 0.04% 5.3% 
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Supplementary Figure 2.3.  Nucleotide sequence of the 5' portion of LDLR 3'UTR  
 
    44156 agacagatgg tcagtctgga ggatgacgtg gcgTGAacat ctgcctggag tcccgcccct 
    44216 gcccagaacc cttcctgaga cctcgccGgc cttgttttat tcaaagacag agaagaccaa 
    44276 agcattgcct gccagagctt tgttttatat atttattcat ctgggaggca gaacaGgctt 
    44336 cggacagtgc ccatgcaatg gcttgggttg ggattttggt ttcttccttt cctgctgaag 
    44396 gataagagaa acaggcccgg ggggaccagg atgacacctc catttctctc caggaagttt 
    44456 tgagtttctc tccaccgtga cacaatcctc aaacatggaa gatgaaaggg Caggggatgt 
    44516 caggcccaga gaagcaagtg gctttcaaca cacaacagca gatggcacca acgggacccc 
    44576 ctggccctgc ctcatccacc aatctctaag ccaaacccct aaactcagga gtcaacgtgt 
    44636 ttacctcttc tatgcaagcc ttgctagaca gccaggttag cctttgccct gtcacccccG 
    44696 aatcatgacc cacccagtgt ctttcgaggt gggtttgtac cttccttaag ccaggaaagg 
    44756 gattcatggc gtcggaaatg atctggctga atccgtggtg gcaccgagac caaactcatt 
    44816 caccaaatga tgccacttcc cagaggcaga gcctgagtca cCggtcaccc ttaatattta 
    44876 ttaagtgcct gagacacccg gttaccttgg ccgtgaggac acgtggcctg cacccaggtg 
    44936 tggctgtcag gacaccagcc tggtgcccAt cctcccgacc cctacccact tccattcccg 
    44996 tggtctcctt gcactttctc agttcagagt tgtacactgt gtacatttgg catttgtgtt 
    45056 attattttgc actgttttct gtcgtgtgtg ttgggatggg atcccaggcc agggaaagcc 
    45116 cgtgtcaatg aatgccgggg acagagaggg gcaggttgac cgggacttca aagccgtgat 
    45176 cgtgaatatc gagaactgcc attgtcgtct ttatgtccgc ccacctagtg cttccacttc 
      
 
 
The stop codon (TGA) is capitalized.  Nucleotide positions are numbered according to the 
LDLR gene sequence in the GenBank database (NC_000019).  Major nucleotides at the six 
SNP sites are shown in blue capital letters.  Underlines indicate the regions highly conserved 
between humans and rodents.  ARE sequences are shown in green letters, a stem loop is 
shown in pink letters, and the positions corresponding to the PCR primers used to amplify 
the 1kb DNA are shown in red letters.  
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Abstract 
 The low density lipoprotein receptor (LDLR) with its ligand apolipoprotein E (apoE) 
plays an essential role in cholesterol homeostasis.  Genetic variations in the human low 
density lipoprotein gene (LDLR) and APOE isoforms have been shown to associate with the 
levels of plasma low density lipoprotein cholesterol (LDL-C).  However, the gene-gene 
interaction between LDLR and APOE in determining the risk of atherosclerosis in humans 
has not been interrogated  
A nucleotide change C44857T in the 5’ region of the 3’UTR of the human LDLR gene was 
genotyped in the Atherosclerosis Risk in Communities (ARIC) study.  Genotyping two 
SNPs in exon 4 of the human APOE gene, T3937C, and C4075T, in ARIC population 
resulted in three isoforms, APOE*2, APOE*3, and APOE*4.  Our results showed that there 
is no interaction between between LDLR and APOE genotypes in ARIC population.  Thus 
LDLR genotype effect and APOE genotype effect are independent. 
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Introduction 
 
LDLR with its ligands apoE and apoB play a pivotal role in cholesterol homeostasis 
(Goldstein 1995; Hobbs et al. 1990).  Mutations in the LDLR gene which lead to a decreased 
expression of LDLR cause familial hypercholesterolemia (FH), a phenomena characterized 
by an accumulation of cholesterol in the circulation and premature coronary heart disease 
(CHD).  Moreover, single nucleotide polymorphisms in the human LDLR gene cause a 
quantitative change of LDLR expression that are associated with either an increased or a 
decreased level of LDL-C and an increased or a decreased risk of atherosclerosis. 
Hypercholesterolemia is a complex and multifactorial disease, and the effect of one 
genetic variation may be interact with the effect of other genetic variations in other genes as 
well as gene environment interaction (Wang and Zhao 2003).  Association studies in the 
LDLR gene and the risk of CHD have been well studied, but the interaction of LDLR gene 
with other genes, mainly those that are involved in lipid metabolism, has been under 
estimated.   
ApoE is a glycoprotein that plays a key role in the clearance of plasma chylomicrons, 
very low density lipoproteins (VLDL), and high density lipoproteins (HDL) via its 
interaction with the low density lipoprotein receptor (LDLR) (Corbo and Scacchi 1999; 
Hussain et al. 1999; Melman et al. 2002b).  In the population there are three common 
isoforms, APOE*2, APOE*3 and APOE*4, with allele frequencies of 0.08, 0.77, and 0.15 
respectively (Banares et al. 2005; Boerwinkle and Utermann 1988a; Weisgraber 1990)  
These isoforms differ in the amino acids at position 112 and 158.  The most frequent 
isoform, APOE*3, has cysteine and arginine at these positions, APOE*2 has two cysteines 
and APOE*4 has two arginines (Lund-Katz et al. 2001; Weisgraber 1990).   
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 The isoforms have different binding affinities for LDLR; apoE4 has a higher binding 
affinity than apoE3, while apoE2 binds very poorly (Lund-Katz et al. 2001; Saito et al. 
2003; Saito H 2003).  Despite its poor receptor binding however, individuals with apoE2 
have a reduced level of cholesterol and a reduced risk of atherosclerosis, except for 5%–10 
% of apoE2 homozygous who develop Type III hyperlipoproteinemia exhibiting, very high 
levels of plasma cholesterol and triglycerides (TG).(Kypreos et al. 2003.).  In contrast, 
individuals with apoE4 have significantly increased plasma LDL-C levels and an increased 
risk of atherosclerosis compared to those without (Banares et al. 2005; Boerwinkle et al. 
1987; Bouthillier et al. 1983; Malloy I 2004)  
 This paradox in binding affinity and atherosclerosis risk has been attributed to the 
high affinity of apoE4 for the receptor resulting in rapid clearance of chylomicrons and 
VLDL remnants causing a down regulation of the LDLR, while the low affinity of apoE2 
results in slow clearance of chylomicrons and VLDL remnants and therefore, an up 
regulation of the LDLR (Davignon et al. 1988).  The increase in LDLR expression 
ameliorated the hyperlipidemia and atherosclerosis of the mice that were homozygous for 
the human APOE*2 isoforms.(Knouff et al. 2001). 
On the other hand, Malloy et al showed that, mice fed a western-type diet, and carry 
the human APOE*4, with an increased expression of LDLR, developed severe 
atherosclerosis due to the accumulation of cholesterol in the plasma (Malloy I 2004).  In 
contrast, there was no harmful effect on mice carrying human APOE*3.  This finding led 
Malloy and his group to postulate an “ApoE Trapping” hypothesis which states that, apo E4 
which has a high affinity for the receptor is trapped by it, and hence render it unavailable for 
the newly formed lipoproteins resulting in an increase in cholesterol levels in plasma.  
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Above observations in mice suggest that there may be gene-gene interaction between 
LDLR and APOE in humans affecting atherosclerosis risk. 
A previous study by Muallem et al showed that the mean LDL-C in C/C rs1433099 
(C44857) homozygous Caucasians male and female was 7.0 and 4.0 mg/dl higher than T/T 
(44857T) homozygous.  Also in C/C homozygous African American female LDL-C was 3 0 
mg/dl higher compared to T/T homozygous.(Muallem et al. 2007).  Since there were no 
functional differences between these 3’UTR sequences, we concluded that C (44857) is 
linked to variations in the LDLR gene and neighboring genes which causes plasma 
lipoprotein profiles associated with high risk for CHD. 
In the present paper, we studied the interaction between a nucleotide change 
rs1433099, C44857T in the 3’UTR of the human LDLR gene and the APOE isoforms and 
their effect on lipid levels in the Atherosclerosis Risk in Communities study. 
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Material and Methods 
 
ARIC study population 
 
 The ARIC study is a prospective epidemiologic study whose main target is to 
investigate atherosclerotic vascular diseases and their risk factors (The ARIC (investigators 
1989).  Blood samples were drawn for the analysis of lipids and lipoproteins and DNA was 
extracted for genotyping (Brown et al. 1993).  The present study includes 13,838 Caucasians 
and 3,481 African Americans.  Fasting plasma lipid data at the first cohort examination visit 
(1987-1989) was used for this analysis. The genotyping strategy for the LDLR and APOE 
polymorphisms have been previously described (Muallem et al. 2007; Sturgeon et al. 2005).  
 
Statistical analysis 
 
 All analyses were stratified by race.  Deviations from Hardy-Weinberg equilibrium 
expectations were tested using a goodness-of-fit test.  Multiple linear regression analysis 
was conducted to evaluate the mean estimated values of TC, LDL-C, HDL-C and LDL/HDL 
ratio in groups of individuals with different LDLR and APOE genotypes.  Individuals with 
the LDLR C44875T C/T genotype and APOE E3 isoform were considered the referent 
group.  The Model evaluated interaction effect between LDLR C44875T genotypes and 
APOE genotypes on these lipid traits, on a multiplicative scale, using multiple partial F test 
for overall effect of interaction terms, with individuals carrying LDLR C44875T C/T and 
APOE E3 genotype as a reference group.  All analyses were performed separately in 
Caucasians and African Americans, using SAS software, version 9.1.3. 
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Results 
 For the purpose of this analysis, LDLR and APO E genotypes were grouped into 
three categories: LDLR C/C, C/T and T/T, C/T the reference group, and APOE*2 (2/2, 2/3, 
2/4), APOE*3 (3/3) the reference group and APOE*4 (3/4 and 4/4).  As shown in table 1 the 
frequency distribution of the combination of LDLR genotypes, C/C, T/T and APOE 
genotypes, E2, E4 are different in African Americans and Caucasians.  Frequencies for 
LDLR C/C: APOE*2, and LDLR C/C: APOE*4 are higher in African Americans than in 
Caucasians (10.1%, 6.1%, vs 1.9%, 1.2%), while Caucasians have higher frequencies for 
LDLR T/T: APOE*2 and LDLR T/T: APOE*4 compared to African Americans (13.6%, 
8.5% vs. 7.2%, 4.0%) Table 3.1. 
 As for the interaction term, no evidence of significant interaction was seen between 
LDLR and APOE genotypes among Caucasians and African Americans in ARIC population. 
Tables 3.2-3.9. 
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Table 3.1.  Frequency of LDLR and APOE interaction stratified by race. 
APOE LDLR 
 CC CT TT 
E2 193 (1.9%)  1406 (13.6%) 
E3  7752 (74.9%)  
Caucasians 
N=13,838 
E4 126 (1.2)  880 (8.5%) 
    
E2 350 (10%)   
E3  2528 (72.6%)  
African 
Americans 
N= 3,481 
E4 212 (6 %)  139 (4%) 
CT and E3 are the reference groups 
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Table 3.2.  Interaction effect between C44875T polymorphisms in LDLR and APOE 
polymorphisms on plasma lipoproteins in Caucasians 
 Total cholesterol*  
APOE LDLR C44875T  
  C/C C/T T/T  
є2 -1.56 ± 2.3 (P=0.498) -11.28 ± 1.76 (P<0.001) -1.84 ± 1.92 (P0.339)  
є3 1.01 ± 1.05 (P=0.338) 0 -6.16 ± 1.95 (P=0.002)  
є4 2.44 ± 4.28 (P=0.569) 6.87 ± 1.47 (P<0.001) 2.7 ± 3.63 (P=0.458)  
P* P = 0.6191  
* Unit of measurement is mg/dl 
Table 3 3.  Interaction effect between C44875T polymorphisms in LDLR and APOE 
polymorphisms on plasma lipoproteins in Caucasians 
  LDL-C*  
APOE LDLR C44875T  
  C/C C/T T/T  
є2 -3.87 ± 2.16 (P=0.074) -13.61 ± 1.66 (P<0.001) -2.65 ± 1.81 (P=0.143)  
є3 1.78 ± 0.98 (P=0.071) 0 -6.04 ± 1.83 (P=0.001)  
є4 0.23 ± 4.04 (P=0.954) 7 ± 1.38 (P<0.001) 2.35 ± 3.42 (P=0.492)  
P* P = 0.2094  
* Unit of measurement is mg/dl 
Table 3 4.  Interaction effect between C44875T polymorphisms in LDLR and APOE 
polymorphisms on plasma lipoproteins in Caucasians 
  HDL*  
APOE LDLR C44875T  
  C/C C/T T/T  
є2 1.35 ± 0.88 (P=0.128) 0.02 ± 0.68 (P=0.972) 0.25 ± 0.74 (P=0.738)  
є3 -1.27 ± 0.4 (P=0.002) 0 -0.68 ± 0.75 (P=0.361)  
є4 0.36 ± 1.64 (P=0.826) -1.34 ± 0.56 (P=0.018) -0.57 ± 1.39 (P=0.683)  
P* P = 0.6216  
* Unit of measurement is mg/dl 
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Table 3 5.  Interaction effect between C44875T polymorphisms in LDLR and APOE 
polymorphisms on plasma lipoproteins in Caucasians 
  LDL/HDL  
APOE LDLR C44875T  
  C/C C/T T/T  
є2 -0.21 ± 0.07 (P=0.005) -0.25 ± 0.06 (P<0.001) -0.06 ± 0.06 (P=0.298)  
є3 0.13 ± 0.03 (P<0.001) 0 -0.08 ± 0.06 (P=0.21)  
є4 -0.11 ± 0.14 (P=0.423) 0.22 ± 0.05 (P<0.001) 0.06 ± 0.12 (P=0.614)  
P* P = 0.0638  
* Unit of measurement is mg/dl 
Table 3 6.  Interaction effect between C44875T polymorphisms in LDLR and APOE 
polymorphisms on plasma lipoproteins in African Americans 
  Total cholesterol* 
APOE LDLR C44875T 
  C/C C/T T/T 
є2 1.45 ± 5.23 (P=0.782) -13.04 ± 2.86 (P<0.001) 0.59 ± 4.3 (P=0.892) 
є3 4.32 ± 2.79 (P=0.121) 0 1.34 ± 2.61 (P=0.608) 
є4 1.57 ± 4.62 (P=0.734) 8.63 ± 2.38 (P<0.001) -1.72 ± 3.93 (P=0.662) 
P* P =0.9653 
* Unit of measurement is mg/dl 
Table 3 7.  Interaction effect between C44875T polymorphisms in LDLR and APOE 
polymorphisms on plasma lipoproteins in African Americans 
  LDL-C* 
APOE LDLR C44875T 
  C/C C/T T/T 
є2 2.58 ± 4.98 (P=0.605) -15.39 ± 2.71 (P<0.001) 3.65 ± 4.09 (P=0.373) 
є3 2.11 ± 2.66 (P=0.427) 0 1.62 ± 2.48 (P=0.514) 
є4 0.08 ± 4.4 (P=0.985) 8.16 ± 2.26 (P<0.001) 1.07 ± 3.74 (P=0.775) 
P* P = 0.9278 
* Unit of measurement is mg/dl 
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Table 3 8.  Interaction effect between C44875T polymorphisms in LDLR and APOE 
polymorphisms on plasma lipoproteins in African Americans 
  HDL* 
APOE LDLR C44875T 
  C/C C/T T/T 
є2 -2.1 ± 2.08 (P=0.313) 1.27 ± 1.14 (P=0.264) -2.05 ± 1.71 (P=0.232) 
є3 1.46 ± 1.11 (P=0.188) 0 -2.06 ± 1.04 (P=0.047) 
є4 1.79 ± 1.84 (P=0.33) -1.36 ± 0.95 (P=0.151) -0.2 ± 1.56 (P=0.9) 
P* P = 0.424 
* Unit of measurement is mg/dl 
Table 3.9.  Interaction effect between C44875T polymorphisms in LDLR and APOE 
polymorphisms on plasma lipoproteins in African Americans 
  LDL/HDL 
APOE LDLR C44875T 
  C/C C/T T/T 
є2 0.08 ± 0.15 (P=0.584) -0.3 ± 0.08 (P<0.001) 0.15 ± 0.12 (P=0.2) 
є3 0.02 ± 0.08 (P=0.769) 0 0.12 ± 0.07 (P=0.113) 
є4 -0.11 ± 0.13 (P=0.376) 0.2 ± 0.07 (P=0.003) 0.09 ± 0.11 (P=0.431) 
P* P = 0.4442 
* Unit of measurement is mg/dl 
*Values were adjusted for age, Weld center, current drinker, current smoker, use of medicine 
to lower cholesterol, use of medicine that secondarily affect cholesterol, BMI and waist to hip 
ratio.  In addition, values were adjusted for formal smokers, menopausal status and current 
hormone usage for women. 
**P value is from the multiple partial F test for overall effect of interaction between C44857T 
polymorphism in LDLR and APOE polymorphisms on total cholesterol, LDL-C, HDL-C and 
LDL/HDL. 
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Discussion 
The effect of gene-gene interaction between LDLR and APOE on lipid profile was 
studied by Pederson and Berg in 1990 and Ahn et al in 1994 (Ahn et al. 1994; Pedersen and 
Berg 1989, 1990).  Pederson and Berg studied the interaction between Pvu II polymorphism 
in intron 15 of the human LDLR and APOE genotypes in 200 unrelated Norwegian subjects.  
They found that individuals having the APOE4 and carrying the Pvu.II positive allele had 
lower total cholesterol than those individuals having APOE4 and carrying the Pvu II 
negative allele linked to TT.  Hence, the increasing effect of APOE4 on cholesterol was 
diminished by the presence of Pvu II positive allele in this study.  On the other hand, Ahn et 
al studied the interaction of two common polymorhisms, Ava II (exon 13) and Nco I (exon 
18) with APOE genotypes in 385 normolipidic Hispanic and 543 non-Hispanic whites, from 
Colorado.  Unlike Pederson and Berge, Ann et al did not find an interaction between LDLR 
and APOE genotypes.  The limitation of the two studies is the small sample size.  Our aim in 
this paper is to study the interaction with a large sample size that has enough power to detect 
gene-gene interaction. 
Gene-gene interaction between LDLR and APOE was detected in Alzheimer’s 
disease (AD) (Cheng et al. 2005).  In this study authors studied two nucleotide changes in 
exon 8 rs11669576 (A24441G) and exon 13 rs5925 (C33078T) in the human LDLR gene for 
functional interaction with APO*E4 isoform in determining the risk of AD.  They found that 
individuals with APOE*4 and who are homozygous for LDLR G/G and C/C at the same two 
SNP sites have a nine fold increase in the risk for AD compared to individuals with other 
combination of LDLR genotypes.  
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Malloy et al showed that in mice, there is an interaction between LDLR and APOE 
genotypes governed by the level of expression of LDLR, APOE genotypes and western type 
diet as mentioned in the introduction.  Mice carrying the human APOE4 and having an 
increased expression of LDLR developed sever atherosclerosis.  In contrast, the increased 
expression of LDLR in mice having APOE2 were protected from the hyperlipidemia and 
atherosclerosis. 
Our analysis using the ARIC population showed that there is no statistically 
significant interaction between LDLR genotypes and APOE isoforms, suggesting that the 
APOE genotype effect and LDLR genotype effect on plasma lipid levels are independent. 
This lack of interaction has to be interpreted with caution.  Even though the strength 
of this study is the large sample size of both Caucasians (13,838) and African Americans 
(3,481), when the samples are divided among LDLR genotypes and APOE isoforms, sample 
size becomes small in some groups.  This reduces statistical power and might limit the 
identification of gene-gene interaction (Moore and Williams 2002). 
Another consideration is the fact that the C44857T SNP studied here is not a 
causative SNP, but it is in linkage disequilibrium with other causative SNPs in the gene.  
Since we do not know the nature of the causative SNPs, and the extent of linkage 
disequilibrium with the C44857T, the small effect associated with this SNP may not be 
sufficient to reveal the interaction with the strong effects of apoE polymorphisms.   
It is, therefore, necessary to identify functional LDLR gene polymorphisms that 
influence the basal level of LDLR expression to test the interaction between the LDLR 
expression and apoE polymorphisms observed in mice. 
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Abstract 
 
 The low density lipoprotein receptor plays an important role in cholesterol 
homeostasis.  Enhancer activities that affect their transcriptional control within the promoter 
region and that located 13 kb downstream of the human low density lipoprotein (LDLR) 
gene have been well characterized, but, regulatory elements residing within the gene have 
not been studied.  We have identified transcriptional enhancer elements within a 100 bp 
fragment in the first intron of LDLR gene.  The 100 bp fragment enhances the luciferase 
activity of a reporter gene when inserted into pGL3-promoter vector by 3.0 fold.  The 
enhancement is orientation independent.  However, neither the fragment containing 5’ half 
of the 100 bp, or that containing only 3’ half of the 100 bp were able to confer the enhancer 
activity.  A sequence motif in the 5’ half is similar to the Sp1 binding site.  Supershift with 
Sp1 polyclonal antibody suggests that Sp1 is necessary but not sufficient for the enhancing 
activity.  A sequence motif AGCTATCCCC in the 3’ half is a potential GATA protein 
binding site.  However, co-transfection with GATA expression vectors did not increase the 
enhancing activity suggesting that the GATA proteins are not involved in controlling 
transcription.  Thus other factors synergistically enhance the transcription of the LDLR gene. 
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Introduction 
 
 The low density lipoprotein receptor (LDLR) is a cell surface receptor that plays a 
pivotal role in lipoprotein metabolism.  Mutations in the LDLR gene cause familial 
hypercholesterolemia which is characterized by an increase in low density lipoprotein 
cholesterol (LDL-C) and premature coronary heart disease (CHD).  Transcription of the 
LDLR gene is regulated by intracellular level of cholesterol (Smith et al. 1990).  When 
intracellular level of cholesterol is low, transcription of LDLR is increased and its amount on 
the cell surface is also increased to actively bind and internalize LDL-C.  On the other hand, 
when cholesterol level within cells is high, transcription is diminished and the uptake of 
LDL-C is suppressed (Dawson et al. 1988).  The basal and cholesterol mediated 
transcription of LDLR depend on elements within 177 base pairs in the promoter region 
which contains two TATA boxes and three GC rich imperfect repeats of 16 bp each (Sudhof 
et al. 1987).  Repeat 1 and 3 contain binding sites for Sp1 transcription factor that are 
responsible for the basal level of LDLR expression.  Repeat 3 contains a sterol regulatory 
element binding site (SRE-1), where sterol regulatory element binding protein (SREBP) 
binds and enhances transcription (Briggs et al. 1993).  Nuclear localization of SREBP is 
regulated by another protein called steroid regulatory element binding protein cleavage 
activating protein (SCAP).  SCAP has a sterol sensing domain (SSD), and when cytoplasmic 
intracellular sterol content is low, SCAP activates site -1 protease (SIP) which cleaves 
SREBP at one site.  The cleaved product is then cleaved by site-2 protease (S2P) and the 
active N-terminal domain of SREBP migrates to the nucleus to initiate transcription (Hua et 
al. 1993; Wang et al. 1994). 
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 In addition to the enhancer activity in the promoter of LDLR, Wang et al identified a 
DNA sequence highly conserved among primates approximately 13 kb downstream of the 
gene.  This PS2 sequence contains SRE binding motif TCACCCCAC which binds SREBP-
2.  The PS2 sequence enhances luciferase gene expression driven by the proximal human 
LDLR promoter.  The activity of the test vector containing LDLR promoter/SREBP-2/PS2 
was 5 fold higher than the vector containing LDLR promoter  
 The 5’region of the LDLR gene is rich in G/C nucleotides. The G/C rich region 
extends well beyond exon I into the 5’portion of intron I.  Many genes with a similar 
sequence feature are known to contain enhancer sequences in their first intron.  For example, 
the human β –enolase gene, Adolase β gene, adiponectin gene, HPRT gene, β actin, smooth 
muscle actin, and adenosine deaminase gene (Aronow et al. 1989; DeLong and Smith 2005; 
Frederickson et al. 1989; Gregori et al. 1998; K Satyamoorthy et al. 1977; Mack and Owens 
1999; Qiao et al. 2005; Reid et al. 1990).  We therefore hypothesized that the G/C rich 
region of intron I of the human LDLR gene may contain transcriptional enhancer activity.  In 
the present paper we identified an enhancer activity in a 100 bp fragment containing a 
binding site for the transcription factor Sp1.  Insertion of the 100 bp into a pGL3-promoter 
vector led to a 3.0 fold increase in luciferase activity in human embryonic kidney 293 cells. 
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Material and Methods 
Plasmid Construction 
 A phage clone containing approximately 10kb of DNA spanning part of the 
promoter, exon I and two third of intron I of the human LDLR gene was obtained by 
screening the lamda phage library (Kim et al. 1990).  The phage DNA was digested with 
EcoR1 restriction enzyme to generate three fragments, Fa1, 2448 bp (859-3307), Fa2, 1668 
bp (3308-4976) and F a3, 4872 bp (4977-9849).  The nucleotide positions are according to 
GenBank accession number AY324609 as shown in Figure 4.1. 
 Each fragment was cloned into EcoR1 site in pBluescript II KS (-) plasmid vector 
(Stratagene).  The correctness of the sequence was verified by sequencing using specific 
forward and reverse pBluescript II KS (-) plasmid primers, M13F3 and M13R3. 
PGL3- promoter vector (Promega) contains a multiple cloning sites, followed by SV40 
promoter, cDNA of firefly luciferase gene (driven by SV40 promoter) and ampicilline 
resistant gene β –lactamase.  The Xho1 site within the cloning site was replaced with EcoR1 
site into which these EcoR1 fragments were inserted.  pR-Tk vector containing cDNA of 
Renilla luciferase (Promega) was used to control for transfection efficiency. 
 
Amplification of fragments Fa5, Fa8 and Fa11 
 DNA fragment, Fa5, that contains the first 823 bp (2489-3312) of intron I, 
was generated by PCR in a 25 µl reaction mixture using Phusion High-Fidelity DNA 
Polymerase kit (BioLabs, New England).  The forward and reverse primers, 5’-GAA 
TTCGTAAGGCTTGCTCCAGGCGC-3’ and 5’-GGTGGCCTGTTCGGACTACA-3’, 
introduced EcoR1 sites at both the 5’ and 3’ ends of the PCR product.  Human genomic 
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DNA (Maeda 1991) was denatured at 98ºC for 30 seconds, followed by annealing 
/elongation at 72ºC for 1.0 minute and 30 cycles.  Fa8, a 100 bp (3730-3830), spanning a 
Bgl2 site within Fa2 fragment was generated using Fast Start High Fidelity PCR System 
(Roche, Indianapolis, IN, USA).  The forward and reverse primers were, 5’-
GAATTCTTGAAACGTTGCCTCAGAAT-3’ and 5’- 
GAATTCACCCCAGGGGGTCGGTCCCG-3’.  The 25µl PCR reaction containing human 
genomic DNA was denatured at 95ºC for 2.0 minutes followed by annealing /elongation at 
72ºC for 1.0 minutes and 35 cycles.  Fa11, a 245 bp (3211–3455) 5’ of the Bgl2 site was 
generated using Fast Start High Fidelity PCR System using the forward and reverse primers: 
5- GAATTCATCCTGAGTTGGGTGCAGTC -3, AND 5’- 
GAATTCACAAGGTGAGGCTCAGACTT-3’.  Amplification conditions are the same as 
Fa8.  The PCR products were run on 0.8% agarose gel, purified using QIA quick gel 
extraction kit 250 (Qiagen Inc, Valencia, CA), digested with EcoR1 and sequenced with the 
PCR primers to verify the sequences.  The purified PCR was cloned into the pGL3- 
promoter and used to test enhancer activities. 
Two clones that contained Fa9, (1169 bp, 3807-4976) and Fa10, (778 bp, 4198-
4976) were obtained by nested deletions with exonuclease III of the clone containing Fa2 in 
the forward direction using Erase a base system (Promega) according to the manufacturer’s 
protocol. 
 
Transient Transfection and Luciferase Activity 
 Human embryonic kidney cells, 293A, were grown in Dulbecco’s modified Eagle’s 
medium (DMEM) supplemented with 10% fetal bovine serum, 2mM L-glutamine, and 
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penicillin - streptomycin.  Cells were grown to 90% confluency in 6mm plates and 
transiently transfected with a mixture containing 10 µl Lipofectamine 2000 
(Invitrogen,Carlsbad, CA) and approximately 0.8 µg DNA composed of 20:1 molar ratio of 
a pGL3-promoter test vector to pRL-TK control vector (Promega, Madison, WI).  Cells 
were incubated in above medium at 37ºC and 5 % CO2 for 24 hours.  Cells were harvested 
and lysed in 300 µl of DMEM medium for luciferase assay.  Luciferase activity was 
determined by using the Dual- Glo luciferase Reporter Assay System (Promega).  For 
Firefly luciferase activity, 75 µl of the lysate was added to 75 µl of Dual-Glo luciferase 
reagent, mixed on a shaker for half an hour and measured using Orion Microplate 
Luminometer.  Subsequently, Renilla luciferase activity (control vector) was measured as 
above, 75 µl of Dual-Glo.Stop& Glo reagent was added to150 µl of the above mixture.  The 
relative activity of the test vector was determined by dividing firefly luciferase activity by 
Renilla luciferase activity.  Each test vector was assayed in triplicate of transfection per 
experiment and the experiment was repeated at least twice.  Co-transfection with the 
GATA’s expression vectors (kindly provided by Dr. T Kodoma at Tokyo U Japan) was 
carried at 1:1 molar ratio (approximately 0.7µg of each vector DNA) with the test plasmid 
that contained Fa8 fragment  
 
Elecrtophoretic Mobility shift Assay 
 A100 bp DNA fragment of Fa8 was cut from agarose, and labeled with [ά- P
32
] 
dCTP using Klenow fragment of polymerase enzyme (Roche, Indianapolis IN) and 6bp 
random oligonucleotides.  Nuclear protein was extracted from 293 cells following the 
manufacturer’s protocol (Active Motif, Carlsbad, CA).  Protein concentration was 
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determined by BCA protein Assay Kit, (Pierce, Boston, MA).  For electrophoretic mobility 
shift assay (EMSA), 7.0 µg of nuclear extract was incubated at room temperature for 30 
minutes with 20 µl reaction mixture containing gel shift binding buffer (5 mM MgCl2, 2.5 
mM EDTA, 2.5 mM DTT, 250 mM NaCl, 50 mM Tris-HCl, (pH 7.5) and 0.25 µg/µl poly 
(dI–dC) in 20 % glycerol (Promega).  25,000 cpm of labeled Fa8 was added to the mixture 
and incubation proceeded for another half an hour.  The whole reaction mixture was loaded 
on a 4% non-denaturing polyacrylamide gel and electrophoresed for one hour and a half at 
170 volts in 0.25 x TEB buffer (22mM Tris-HCl, 22mM boric acid and 0.5mM EDTA).  
Gels were dried and the image was analyzed by autoradiography  
 For competition assay, 200 molar excess of cold competitive or non competitive 
DNA fragments were added to the above EMSA reaction mixture.  For supershift assay, 4 
µg of antibodies against human Sp1, GATA1, GATA2, GATA3, GATA4 and GATA6 
(Santa Cruz Biotechnology, CA) were added to the reaction mixture containing labeled 
DNA, binding buffer and nuclear protein (Mack and Owens 1999). 
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Results 
Identification of a DNA sequence with a transcriptional enhancer activity in intron I of 
the human LDLR gene 
 To identify the regulatory sequence (s) in intron I, a phage clone containing part of 
the promoter, exon I and two third of intron I was digested with EcoR1 to produce Fa1, Fa2 
and Fa3 as shown in Figure 4.1. 
 
245bp 
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Figure 4.1.  A schematic representation of the 5’portion of the human LDLR and DNA 
fragments studied.  Fa1, Fa2, and Fa3, were generated by digestion of a phage clone with 
EcoR1.  Nucleotide position was indicated according to Accession number AY324609.  
Double arrowed lines indicate fragments used to generate test vectors.  Fa4 was not 
examined. 
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 DNA fragments, Fa1, Fa2, and Fa3, were cloned separately into pGL3-promoter 
vector upstream of the luciferase gene.  To test their enhancer activities, test plasmid DNAs 
were co- transected into 293 cells with pRL-TK plasmid as a transfection control.  Test 
vector containing fragment Fa1 gave a slightly higher luciferase activity than the pGL3 
vector (1.6±0.12 vs 1.0±0.24, p<0.01) (Figure 4.2).  This activity was probably due to the 
promoter region, since a test vector with PCR fragment, Fa5, which contains the beginning 
of intron I but not promoter and exon I showed a luciferase activity that was not statistically 
different from the control vector pGL3 (Figure 4.3).  In a marked contrast, test vector with 
Fa2, showed 3.7 fold higher activity than the pGL3 vector (3.7±0.180 vs 1.0±0.024, 
p<0.001) (Figure 4.2).  The luciferase activity of the lysates of the cells transfected with the 
test vector containing Fa3 was not statistically significant from the pGL3 vector. 
 The enhancer element, by definition, should enhance transcription of nearby genes in 
an orientation independent fashion.  To test whether enhancement by the Fa2 fragment is 
orientation independent, the 1.6 kb EcoR1 fragment was inserted into PGL3 vector in a 
reverse orientation, Ra2.  The luciferase activity in the cells transfected with Ra2 test vector 
was also significantly enhanced and indistinguishable from the activity in the cells 
transfected with Fa2.  Thus 1.6 kb EcoR1 fragment in intron I of the LDLR gene contains an 
enhancer element (s). 
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Figure 4.2.  Analysis of enhancer activity of the DNA fragments, Fa1, Fa2, Ra2, (Fa2 in 
reverse direction) and Fa3, from intron I of LDLR.  The results were expressed as relative to 
the luciferase activity of cells transfected with a control vector PGL3 as 1.  Transfcetion was 
carried in triplicate in each experiment, and the experiment was repeated three times.  Bars 
indicate means ±SE from these experiments.  * indicates the significant difference from the 
activity of PGL3, p<0.01. 
 
 
 
 
 
 
* 
*              * 
  91 
 
 
 
 
pGL3 Fa1 Fa5
0
1
2
R
e
la
ti
v
e
 L
u
c
if
e
ra
s
e
 A
c
ti
v
it
y
 
Figure 4.3.  Analysis of enhancer activity in the first part of intron I.  Fa5 is Fa1 excluding 
the promoter and exon I.  Transfcetion was carried in triplicate in each experiment, and the 
experiment was repeated three times.  Bars indicate means ±SE from these experiments.  * 
P<0.01 compared to PGL3. 
 
 
 
 
 
 
 
 
 
* 
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 To further localize the position of elements responsible for the enhancer activity 
within Fa2, we digested the fragment into two, Fa6, (470 bp, 3308-3777) and Fa7, (1198, 
3778-4976) by cutting it at the unique Bgl2 restriction site (Figure 4.1), and cloned them into 
EcoR1/Bgl2 sites of the PGL3 vector.  Transfection into 293 cells revealed that neither Fa6 
nor Fa9 conferred enhancer activity (Figure 4.4),  Luciferase activity in the cells transfected 
with Fa6 test vector was the same as with the control PGL3 activity; while the activity of the 
Fa7 vector was significantly reduced (0.32±0.04 vs1.00±0.04, p<0.01).  We tested two 
independent clones of the test vectors, and the results were the same.  Thus cutting at the 
Bgl2 site led to the loss of enhancer activity of Fa2. 
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Figure 4.4.  Loss of enhancer activity of Fa2 by cutting at the Bgl2.  Fa6 is 470 bp of the 
5’portion and Fa7 is 1198bp of the 3’portion of fragment Fa2.  Transfcetion was carried out 
in triplicate in each experiment, and the experiment was repeated three times.  Bars indicate 
means ±SE from these experiments.  * P<0.01 compared to PGL3. 
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 We also tested the activity of vectors containing sequences Fa9, (1169 bp), and Fa10 
(778 bp), that are 3’parts of the Fa7 (Figure 4.1).  The luciferase activity of cells transfected 
with Fa10 was slightly higher than that of cells transfected with PGL3 (1.2±0.1 vs 1.0 ±0.04 
p<0.0 1) (Figure 4.5), but Fa9 did not show any enhancing activity.  The suppression seen in 
Fa7 was absent in either Fa9 or Fa10, suggesting that if a negative enhancer is present with 
Fa7, it is likely located within 29 bp of its 5’ portion (3778-3807) of Fa8. 
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Figure 4.5.  To locate the base pairs responsible for the decreased activity in Fa7. 
Fa9 is 1169 bp and F10 is 778 bp of the 3’portion of Bgl2 cutting site.  Transfcetion was 
carried in triplicate in each experiment, and the experiment was repeated three times.  Bars 
indicate means ±SE from these experiments.  * P<0.01 compared to PGL3. 
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Enhancer activity lies within 100 bp (Fa8) of Fa2 flanking a Bgl2 site 
 
The loss of activity by cutting at the Bgl2 site led us to hypothesize that the region 
important for the enhancing activity of the Fa2 locates near this site.  To test this, we made a 
100 bp DNA fragment, Fa8, containing 50 bp on either side of the Bgl2 site by PCR.  As 
shown in Figure 4.6, Fa8 was sufficient for 3.7 fold increase of luciferase activity over the 
empty vector as there is no statistical difference between the relative luciferase activities of 
Fa8 containing vector compared to the vector of Fa2 inserted in both directions.  We 
concluded from this experiment that the enhancer element (s) localizes within the 100 base 
pairs of DNA flanking the Bgl2 site. 
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Figure 4.6.  Enhancer activity is located in 100 bp within Fa2.  Transfcetion was carried in 
triplicate in each experiment, and the experiment was repeated three times.  Bars indicate 
means ±SE from these experiments.  * P<0.01 compared to PGL3. 
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We first examined whether the 100 bp, Fa8, sequence contains any known 
transcription factor binding sites using programs available in websites: (http://tfbind.hgc.jp 
and http://www.cbrc.jp/htbin/nph-tfsearch).  The search revealed among others three 
potential sites highly homologous to consensus binding sites for SREBP, GATA and Sp1 as 
shown in Figure 4.7.   
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             Figure 4.7.  DNA sequence of Fa8 Potential transcription binding sites 
 
 
 
 
 
 
 
 
 
Bgl2 
 
  TTGAAACGTTGCCTCAATCTCCCCGCCCCTC 
CTTGGTCTGCAGCCG AGATCTTCAGCCACGGTG 
 
    
GATA    
GGGCAGCTATCCCCCGGGGACCGACCCCCCTGGGGT 
 
SREBP/Sp1  
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SREBP is not the transcription factor that binds to Fa8 
Since SREBP is known to regulate the LDLR gene expression, we next tested 
whether the enhancer activity is influenced by the cholesterol content in the culture medium.  
To do so, 293 cells were cultured in a lipoprotein free medium for 24 hrs, prior to 
transfection, and continued in culture after transfection in either a lipoprotein free medium – 
cholesterol (induction), or in a medium containing cholesterol and OH cholesterol 
(Suppression).  The effectiveness of the system was tested using a test vector which contains 
Fa1 that has a known SREBP site in the promoter region.  As Figure 4.8 A shows, the 
luciferase activity from the Fa1 test vector transfected cells was significantly induced in 
lipoprotein free medium and suppressed in cholesterol containing medium.  In contrast, the 
activity of the cells transfected with Fa8 test vector was not influenced by the amount of 
cholesterol in the medium.  We concluded from these results, that SREBP is not likely to be 
involved in the enhancing activity of Fa8. 
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Figure 4.8.  SREBP effects on enhancer activities of Fa1 (A) and Fa8 (B).  Transfcetion was 
carried in triplicate in each experiment, and the experiment was repeated three times.  Bars 
indicate means ±SE from these experiments.  chol=cholesterol.  * P<0.01 between 
suppression and repression media. 
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Effects of GATA transcription factors 
 To identify if GATA transcription factors bind to fragment Fa8, we tested the 
activity of the test vector containing Fa8 alone compared to the same vector co-transfected 
with GATA1-6 expression vectors.  The result of this experiment was in conclusive since as 
seen in Figure 4.9 the activity of Fa8 was statistically different from the activity of GATA1-
6 (p<0.001). 
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Figure 4.9.  To test if GATAs transcription factors bind to Fa8.  Transfcetion was carried in 
triplicate, and the averages of the three plates from a single experiment are shown.  Bars 
indicate means ±SE from one experiment.  * P<0.001 compared to Fa8. 
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To check if GATAs expression vectors work in a dose dependent manner, we repeated the 
same experiment as above with GATA1, GATA5 and GATA6 with decreasing doses (0.38, 
0.25 and 0.1 µg).  The test vector containing Fa8 was co-transfected with 0.38, 0.25 and 0.1 
µg of GATA1, GATA5 and GATA6.  The activity of the test vector containing Fa8 alone 
was not statistically different from the activity of the same vector co-transfected with 
GATA1, GATA5 and GATA6 with the three doses (Figure 4.10).  
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Figure 4.10.  Co-transfection Fa8 with GATA1, GATA5 and GATA6 in a dose dependent 
manner.  Transfcetion was carried in triplicate in the experiment and the experiment was 
done once.  Bars indicate means ±SE from one experiment. 
* P<0.001 compared to Fa8. 
A, B and C = Co-transfection Fa8 with 0.38, 0.25 and 0.1 µg of GATA1 
D, E, and F = Co-transfection Fa8 with 0.38, 0.25 and 0.1 µg of GATA5 
G, H, and J = Co-transfection Fa8 with 0.38, 0.25 and 0.1 µg of GATA6 
 
 
 
GATA1 GATA5 GATA6 
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We next repeated the same experiment as above with GATA5 alone in a dose dependent 
manner but in the increasing order.  The test vector containing Fa8 was co-transfected with 
1.5 and 2.0 µg of GATA5.  The activity of the test vector containing Fa8 alone was not 
statistically different from the activity of the same vector co-transfected with GATA5 at the 
two doses (Figure 4.11).  
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Figure 4.11.  Co-transfection Fa8 with GATA5 in a dose dependent manner.  Transfcetion 
was carried in triplicate in the experiment, and the experiment was done once.  Bars indicate 
means ±SE from one experiment.  * P<0.001 compared to Fa8. 
A = Co-transfection Fa8 with 1.5 µg of GATA5 
D = Co-transfection Fa8 with 2.0 µg of GATA5 
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All of the above results indicate that co-transfection of GATA,s do not influence the 
enhancer activity of fragment Fa8.  The dose dependent experiments were repeated with the 
empty vector and the results were the same.  There was no statistical difference in the 
activity of the PGL3 compared to the activity of the empty vector co-transfected with 
GATAs. 
 
SP1 is likely involved in the enhancing activity of Fa8 
In order to identify the potential transcription factor(s) that bind to the enhancer 
element(s) that localize within the Fa8 fragment, a band shift assay with 293 cells nuclear 
extract was performed.  As seen in Figure 4.12 A, when the labeled 100bp Fa8 fragment was 
incubated with the nuclear extract, a complex was formed as a discrete band that migrated 
slower than the free or unbound DNA on the gel (lane 2).  Incubation with 200 molar excess 
of cold Fa8 fragment decreased the intensity of the band indicating that the binding is 
specific (lane 3), while incubation with 200 molar excess of oligonucleotides containing 
AP2 sequence (promega) showed no competition (lane 4).  Moreover, incubation with 200 
molar excess of Fa11 located upstream of Fa8 that contains multiple potential Sp1 binding 
sites also showed competition (Figure 4.12 B, lane 3).  Incubation with 200 molar excess of 
DNA sequence 5’-ATTCGATCGGGGCGGGGCGAGC-3’ containing SP1 binding site 
(Promega) also showed competition (Figure 4.12 B, lane 4). 
 To verify that Sp1 binds to the Fa8 sequence, we performed a super shift assay with 
polyclonal antibody against Sp1.  As shown in lane5 of Figure 4.12 A, the addition of Sp1 
antibody resulted in a super shift of the nuclear extract probe complex, indicating that the 
shift band contained Sp1.   
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 To test if GATA transcription factors bind to Fa8 sequence, we performed super shift 
assay with antibodies against GATA1 GATA 3 and GATA 4 as seen in Figure 4.12 C (lane 
3, 4 and 5), the nuclear extract probe complex was not shifted.  Addition of antibodies 
against GATA2 and GATA6 also did not result in super shift (Figure 4.12 D lane 3 and lane 
4). 
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Figure 4.12.  DNA mobility shift assay.  (A) 7.0 µg of nuclear extract of 293 cells were 
incubated at room temperature for 30 minutes with 20 µl reaction mixture containing gel 
shift binding buffer as mentioned in material and methods.  25,000 cpm of labeled probe 
was added to the mixture and incubation proceeded for another half an hour.  The samples 
were loaded on a 4% non-denaturing polyacrylamide gel and the DNA: protein complex was 
analyzed by autoradiography (lane 2).  For competition assay, 200 molar excess of cold 
competitive inhibitor (lane 3) and non competitive inhibitor (lane 4) were added to the above 
reaction before the addition of the labeled probe.  Super shift was observed upon the 
addition of 4 µg of Sp1 antibody in the mixture before the addition of labeled probe (lane 5).  
No super shift band was seen with GATA1 antibody (Lane 6).  (B) Incubation with 200 
molar excess of Fa11 showed competition (lane 3).  Incubation with 200 molar excess of 
SP1 sequence 5’-ATTCGATCGGGGCGGGGCGAGC-3’ also showed competition (lane 4).  
(C) 4 µg of GATA1 (lane 3), GATA3 (lane 4), and GATA4 (lane 5) antibodies were assayed 
for super shift as for SPI.  (D) GATA2 (lane 3) and GATA 6 (lane 4) antibodies were 
assayed for super shift as above. 
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Discussion 
 In the present study we have identified in intron I of the human LDLR gene a DNA 
sequence that enhances transcription of a reporter gene.  Previous studies have shown 
enhancer activity within the promoter which is governed by three direct repeats.  Repeat 1 
and 3 bind Sp1 transcription factor to drive the basal level of transcription, while repeat 2 
binds the sterol regulatory element binding protein (SREBP) to the sterol regulatory element 
(SRE) to drive the cholesterol mediated transcription.  Recently, Wang et el also showed 
that there is an enhancer activity approximately 13 kb downstream of the LDLR gene. 
Losing enhancer activity by cutting at the Bgl2 site within the Fa8 led us to speculate 
that another transcription factor is also necessary for the full activity.  But, when the 
transcription factor binding sites were physically separated by cutting at Bgl2 site, there was 
a complete loss of function of the enhancer.  This finding led us to speculate that the 
presence of at least two transcription factors one binding to 5’ and the other binding to 3’ to 
the Bgl2 sites are necessary for the enhancing activity. 
 The result of the supershift with the Sp1 polyclonal antibody suggests that Sp1-
binding is the likely factor that is necessary but not sufficient for this activity.  Sp1 is 
ubiquitously expressed and beside its role in recruiting the basal transcription machinery, it 
also works with other transcription factors to control specific gene expression (Gyrd-Hansen 
et al. 2002; Martino et al. 2001; Qin et al. 1999).  For example, Qin et al showed that Sp1 
and Ap2 are both important for the costitutive matrix metallproteinase-2-gene (MMP-2) 
expression in astroglioma cells.  Mutations in Sp1 A site reduceded MMP-2 transcription by 
41-70 % compared to the wild type, while mutation in Ap2 caused 36-60 % reduction in 
transcription compared to the wild type.  Double mutations at binding sites Sp1A and Ap2 
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decreased transcription to 74-94%, which means that both Sp1 and Ap2 are functionally 
important for transcription of metallproteinase-2-gene expression.   
Sp1 is also well known to interact with other transcription factors including GATAs.  
Both Sp1 and GATA proteins have zinc finger domain which facilitate the interaction 
between them through their finger region.  However, our experiments showed that the 
luciferase activity in the cells transfected with Fa8 test vector was not statistically significant 
from the activity of Fa8 test vector co-transfected with GATAs expression vectors.  Hence, 
this implies that the Sp1 binding partner is a different transcription factor and not the 
GATAs transcription factors.  Hence, further work is necessary to identify the other 
transcription factor (s).   
In the present study we verified the presence of an enhancer within intron 1 of the 
human LDLR gene and identified the transcription factor Sp1 that bind to specific 
sequences.  Regardless of the precise mechanism of the transcriptional activity 
enhancement, we pointed out that there are several SNP sites near to this 100 bp sequence.  
It would also be important to verify whether the nearby polymorphisms have any effects on 
the enhancer activity. 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter V 
 
 
                    Variations in the human low density lipoprotein receptor 
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 In this chapter I will summarize the well studied genetic variations i.e. the single 
nucleotide polymorphisms and the haplotypes that have been identified in the human low 
density lipoprotein receptor gene (LDLR), and have been associated with serum level of total 
cholesterol (TC) and low density lipoprotein cholesterol (LDL-C) in normalipidic 
individuals.  As I have mentioned earlier, the LDLR gene plays an important role in 
cholesterol homeostasis, hence any identification of genetic variations that affect the level of 
TC and LDL-C is important in the human population.  While the individual SNPs may not 
be causative, they are in linkage disequilibrium with other causative SNPs in the gene or 
neighboring genes.  Beside the fact that some of these variations in the LDLR are associated 
with familial hypercholesterolemia, others contribute to the variations in TC and LDL-C in 
normal individuals.   
 
Restriction fragment length polymorphisms 
Early studies used restriction fragment length polymorphisms (RFLPs) to detect 
genetic variations in the human LDLR gene.  For example, Schuster et al in 1990 analyzed in 
324 normocholesterolemic individuals in Germany between the presence and absence of 
sites for the restriction enzymes Stu I (exon 8) Pvu II, ApaLI (intron 15) and Nco I (exon 18) 
and their association with plasma lipid levels.  They found that the presence of Pvu II was 
significantly associated with lower LDL-C by 3.0 mg/dl.  Of the sixteen possible RFLP 
haplotypes, nine were detected in this population and only four were common.  As 
summarized in Table 5.1, the carries of haplotype 3 had lower LDL-C than the sample mean 
(average excess) by 
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by, - 9.49 mg/dl.  Carriers of Haplotypes 2 and 4 were associated with a very small 
reduction of LDL-C by, - 0.15 mg/dl and – 0.41 mg/dl.  While carriers of haplotype 1 
showed a modest increase of LDL-C by 1.44 mg/dl (Schuster et al. 1990; Templeton 1987). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  117 
 
 
 
 
 
 
 
 
 
 
Table 5.1.  Deduced haplotypes of four RFLPs in subjects from Germany.   
Haplotype Stu I 
Exon 8 
ApaLI 
Intron 15 
Pvu II 
Intron 15 
Nco I 
Exon 18 
Frequency 
% 
Average Excess 
mg/dl* 
1 + + - + 27 +1.44 
2 + - - - 25 -0.15 
3 + - + + 20 -9.49 
4 + + - - 12 -0.41 
+ The presence of the cutting site, - the absence of the cutting site. 
*mg/dl LDL-C.  Four common haplotypes out of sixteen total haplotypes. 
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Smilarly, in 1991 Humphries et al studied four RFLPs detected by the enzymes, Ava II, 
(exon 13), Pvu II (intron 15) and ApaLI (3’UTR) in 289 normolipidic individuals in Italy 
(table 5.2).  They also found that the presence of the Pvu II site in intron 15 had an average 
excess of LDL-C by - 9.0 mg/dl.  Of the nine RFLP haplotypes identified, four were 
common.  Haplotype 1 that contains the Pvu II site was associated with an average excess of 
LDL-C by - 11.5 mg/dl.  Haplotypes 2-4 were associated with an average excess LDL-C of 
+ 8.35 mg/dl, + 4.55 mg/dl, and + 3.05 mg/dl respectively as seen in Table 5.2.   
         Clearly these two studies concur and demonstrate that the major effect is defined by 
the presence or absence of Pvu II site in intron 15, and other sites are less important. 
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Table 5.2.  Common haplotypes in normolipidic individuals from Italy. 
Haplotype Ava II 
Exon 13 
ApaLI 5’ 
Intron 15 
Pvu II 
Intron 15 
ApaLI 3’ 
3’UTR 
Frequency 
% 
Average Excess 
mg/dl* 
1 - - + + 27 - 11.5 
2 - + - + 6.2 + 8.35 
3 + + - + 43.5 + 4.55 
4 - - - - 17.9 + 3.05 
+ presence of a cutting site, - absence of a cutting site 
ApaL1 5’, cutting site in intron 15, and ApaL1 3’, cutting site in the 3’UTR. 
* mg/dl of LDL-C.  Four common haplotypes out of nine total haplotypes. 
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 Ava II in exon 13 and Nco I in exon 18 were also studied by Ahn and his group in 
1994 in 385 normolipidic Hispanic and 543 non-Hispanic whites, from Colorado.  The Ava 
II positive allele was associated with significantly increased TC and LDL-C by 6.52 mg/dl 
and 4.95 mg/dl in non-Hispanic women and 3.69 mg/dl and 2.29 mg/dl in Hispanic women.  
The Ava II negative allele decreased significantly TC and LDL-C by 4.84 mg/dl and 3.68 
mg/dl in non-Hispanic women; similar reduction was seen in Hispanic women.  Nco I 
positive allele was also associated with significantly increased TC and LDL-C by 3.66 mg/dl 
and 3.07 mg/dl but only in Hispanic women.  The Nco I negative allele decreased 
significantly TC and LDL-C by 8.99 mg/dl and 7.55 mg/dl in Hispanic women (Ahn et al. 
1994).  There was no effect of these two SNPs in men.  Although both SNPs are in exons, 
amino acid sequence of LDL receptor is not altered by either nucleotide change. 
 Finally, not all studies have shown that these sites are important.  In 1998 Taylor et 
al studied four RFLPs generated by the restriction sites, Stu I (exon 8), Pvu II, ApaLI (intron 
15) and Nco I (exon 18) in a sample of 484 normolipidic individuals in London  Authors 
found that there was no statistical difference in the mean level of serum TC and LDL-C 
among all the genotypes (Taylor et al. 1988).  The subjects were Caucasian males and 
females.  The discrepancy in the effect of Pvu II positive allele among Taylor’s population 
and Humphries and Schusters’s population may be attributed to the fact that different 
populations may have different gene-gene interaction as well as gene environment 
interaction, hence masking the effect of Pvu II on LDL-C in this population.   
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Single nucleotide polymorphisms in LDLR gene 
Studies have been shifted in recent years to the analysis of SNPs in the LDLR gene.  
For example, Boright et al in 1998 studied the association of a polymorphism rs688 
(C1773T) in exon 12 to LDL-C levels in a normolipidic sample of 719 Alberta Hutterites.  
They found that the average effect (from the sample mean) of 1773T allele on LDL-C was + 
3.9 mg/dl, while the average effect of C1773 allele LDL-C was - 6.2mg/dl.  The influence of 
the two alleles is small but significant.  This nucleotide change within exon 12 does not 
change the amino acid, hence authors concluded that it is in linkage disequilibrium with 
other functional variants (Boright et al. 1998).  However, as being described below, this 
polymorphism may also have a functional significance. 
 Knoblauch et al in 2002 studied the effect of common SNP Haplotypes of the LDLR 
gene in 732 individuals in Germany.  They showed that SNPs in LDLR: rs5930 (G26462A 
Exon 10), rs5925 (A33078G Exon 13), rs5927 (C36138T.Exon 15), fall into 7 haplotypes: 
GTG, GTA, GCG, GCA, ATG, ATA, and ACG.  The only haplotype that was associated 
with lipid profiles was GTG, the presence of which was associated with a significant 
decrease of TC by 0.32 mg/dl and LDL-C by 0.41 mg/dl in 102 individulas (Knoblauch et 
al. 2002). 
 Authors extended their study to include extra SNPs, rs2228671 (C13109T Exon 2), 
rs885765 (A18896C Intron 4), rs5930 (G26462A Exon 10), rs5925 (A33078G Exon 13), 
rs5927 (C36138T Exon 15), Pvu II intron 15, C/T and rs1433099 (C44857T 3’UTR).  
Twenty two haplotyes were conferred in 1054 subjects in Germany. Authors concluded 
(2004) that the contribution of the LDLR haplotypes to the genetic variance of LDL-C was 5 
%, HDL-C 6% and LDL/HDL 2% (Knoblauch et al. 2004).  None of the above 
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polymorphisms have been reported to have functional influence, and therefore are thought to 
be in linkage disequilibrium with a causative polymorphism (s). 
In 2007 we studied the haplotypes of four SNPs within the 5’ region of  
the 3’UTR ,rs14158 (G44243A), rs2738465 (G44695A), rs1433099 (C44857T) rs2738466 
(A44964G).  We further sought association of the three common haplotypes, GGCGCA, 
AGCACG, and GGCGTA, with total plasma cholesterol and LDL-C among subjects in the 
Atherosclerosis Risk in Communities (ARIC) study.  The mean LDL-C levels were 7 mg/dl 
and 4 mg/dl higher in C/C (44857) homozygous Caucasian males and females than 
T/Thomozygotes.  LDL-C levels in African American females were 3 mg/dl higher in C/C 
homozygous compared to T/T homozygotes.  In contrast, no effects of C44857T on LDL-C 
levels were detected in African American males.  The A44965G polymorphism had no 
effects on the lipid profiles in either population.  When haplotypes were analyzed, we found 
that Caucasian men with TA/TA haplotypes had 6.06 mg/dl lower TC and, 6.10 mg/dl lower 
LDL-C.  In contrast, Caucasian men with the CA/CA haplotype had 2.46 mg/dl higher LDL-
C.  Caucasian women with the TA/TA haplotype had 4.07 mg/dl lower TC, and 4.63 mg/dl 
lower LDL-C.  There was no effect of these haplotypes on African American men and 
women (Muallem et al. 2007).  The contribution of the 3’UTR haplotypes in Caucasians to 
the genetic variance of LDL-C, HDL and LDL/HDL is consistent with Knoblauch et al‘s 
finding.  The importance of our work is that it is the first study to investigate a large number 
of normolipidic subjects of both Gaucasians and African Americans. 
 A potential polymorphism associated with alteration in the LDLR expression was 
recently reported by Zhu and his group in 2007.  These authors studied the function of a 
SNP rs688 (C1773T) in exon 12, which is common in many populations as European 
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Caucasians, African populations and some Asian populations.  It has a frequency of 
approximately 60% in Caucasians  This SNP was first identified by leitersdorf and Hobbs in 
1988 (Leitersdorf and Hobbs 1988) and was studied for association by Boright (Boright et 
al. 1998).  Zhu et al found by examining LDLR expression in the liver biopsy samples that 
the 1773T allele decreased significantly the splicing efficiency of exon 12 in females.  Cells 
in females homozygous for 1773T allele had a decreased splicing efficiency by about 8.6% 
compared to females homozygous for the 1773 C allele.  The 1773T allele leads to an 
increased amount of LDLR transcripts lacking exon 12 that results in shifting of the reading 
frame and premature terminational protein.  In this study 1773T allele was found to be 
associated with 10 % increase in TC and LDL-C in premenopausal women.  On the other 
hand, the decrease in splicing efficiency was not significant in males and hence there was no 
association of this SNP with LDL-C among men (Zhu et al. 2007).  The lack of association 
between rs688 and LDL-C in males could be explained by the gender difference in exon 12 
splicing efficiency between males and premenopausal females.  This difference could be due 
to the modulating effect of estrogen on the SRp40, the predicted splicing factor that binds to 
exon splicing enhncers (ESE).  The C1773T does not alter the amino acid sequence, but is 
within the exon enhancer splicing region.  This is the first potential functional common SNP 
reported in the human LDLR beside the functional work that was intensively done on the 
promoter portion of the gene by Goldstein, Hobbs and their group. 
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Linkage disequilibrium in LDLR gene 
Having found association between SNPs in the LDLR gene and the lipid profile, and based 
on the fact that only one SNP rs688 in exon 12 is functional, the question remains as to 
whether all other SNPs associated with plasma LDL-C are in linkage disequilibrium with the 
functional rs 688.  Humphries and his group found that Ava II, ApaLI, (5’ and 3’) and Pvu II 
are in linkage disequilibrium however, the main effect on LDL-C is the presence of Pvu II 
allele.  The effect of Pvu II positive allele is not due to Pvu II per se, because pvu II is 
located in intron 15, hence it requires that it should be in linkage disequilibrium with another 
functional polymorphism 
 In addition, Ahn and his group showed that Ava II and Nco I are in linkage 
disequilibrium in both Hispanic and non-Hispanic populations and they both increase the 
level of TC and LDL-C in the two populations.  The presence of both polymorphisms in a 
coding sequence resulting in synonymous amino acids is suggestive that they are not 
functional.  Rather they are in linkage disequilibrium with other functional SNPs else where 
in the gene.  Using Perlegen Genome Browser to detect linkage disequlibrium blocks in 
human LDLR gene in Caucasians, showed that AvaII in exon 13 is in linkage disequilibrium 
with rs688 (C1773T) in exon 12 due to their physical proximity.  Zhu et al showed that this 
rs688 is functional because females homozygous for T/T have decreased exon 12 splicing 
efficiency by 8.6% compared to females homozygous for C/C.  Hence, the increasing effect 
of AvaII and NcoI positive alleles on LDL-C may be explained by the linkage 
disequilibrium of these two SNPs with the functional rs668 that has the similar effect on 
LDL-C.  Moreover, the 3 SNPs did not show any effect in men. 
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 The effect of the four SNPs in the 3’UTR region of the gene, three of which are in 
linkage disequilibrium, (rs14158, rs2738456 and rs2738466) on LDL-C studied by Muallem 
et al is not due to the 3’UTR sequence per se but others that are in linkage disequilibrum 
with them.  Since it is possible that the effect is due to rs688, we searched HapMap phased 
haplotypes of the 2 SNPs and we found that approximately 86 % of the individuals having 
rs1433099 44857T in the 3’UTR in Caucasians, also have rs688 1773C in exon 12 
indicating that 44857T and 1773C are completely linked and both have a lowering effect on 
LDL-C.  On the other hand, we found that approximately 60 % of individuals having 
C44857 also have C1773 and the other 40 % have 1773T indicating that linkage is low.  
Hence, the effect of C44857 on LDL-C is dependent on the linkage with either 1773T that 
decreases LDLR or 1773C that increases LDLR. 
 On the other hand, rs688 is not studied in African Americans, implying that 
C44857T may be in linkage disequilibrium with other SNP in the gene.   
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Figure 5.1.  Map of the polymorphisms mentioned in this chapter and their location in the 
gene. 
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Figure 5.2.  Linkage disequilibrium in the human LDLR gene copied from HapMap 
Genome Browser (http://www.hapmap.org).  LD plot is from CEU population from 
HapMap.  Darker regions implicate higher LD calculated by pairwise r2-values between 
markers. 
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Association of LDLR SNPs and coronary heart disease 
 Even though coronary heart disease is caused by familial hypercholesterolemia (FH), 
an inherited autosomal dominant disease with hallmarks of elevated plasma LDL-C levels as 
a result of mutations in the LDLR gene, most individuals who suffer from CHD do not have 
FH and their plasma lipoprotein levels are within the reference range. 
For example, Salazar et al in 2000 studied the association of the Pvu II 
polymorphism with difference in lipid concentration in 228 white subjects with high and low 
risk of coronary heart disease in Brazil.  Consistent with other observations, the presence of 
Pvu II was associated with decreased TC and LDL-C levels in the Brazilian population.  The 
Pvu II positive allele frequency in individuals with high risk group was 0.25 compared to 
low risk group.  In addition, the Pvu II positive allele was also found at a higher frequency 
among elderly people over the age of 65 suggesting that the allele may be associated with 
longer survival  
In addition, in our study we found that 22 % Caucasian men homozygous for the 
CA/CA diplotype had a significantly higher LDL-C and significant lower HDL-C levels.  As 
a result, they also had a 4.5% higher LDL/HDL ratio, an established risk factor for CHD 
(Panagiotakos et al., 2003).  Conversely, 8 % Caucasian men that were homozygous for the 
TA/TA diplotype had significantly lower total cholesterol and LDL-C, and a 5.3% lower 
LDL/HDL ratio.   
 Recently, Willer et al studied the effect of some genetic variants in several genes 
affecting lipid metabolism including LDLR.  They found that a SNP rs6511720 (G4504T) in 
intron I of LDLR increased LDL-C by 9.17 mg/dl.  This SNP was approximately 1.2% more 
common among coronary artery disease (CAD) cases than in the control group (Willer et al. 
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2008).  Hence, SNPs in LDLR gene are a good genetic marker to predict the risk of CHD in 
the population. 
In summary, the LDLR gene is one locus with multiple alleles.  Association studies 
of single nucleotide polymorphisms in LDLR with lipid parameters have been well studied.  
Extra work is required to investigate more functional polymorphisms beside the rs688 
present in exon 12. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  130 
References 
Abifadel M, Varret M, Rabes JP, Allard D, Ouguerram K, Devillers M, Cruaud C, 
Benjannet S, Wickham L, Erlich D, Derre A, Villeger L, Farnier M, Beucler I, Bruckert E, 
Chambaz J, Chanu B, Lecerf JM, Luc G, Moulin P, Weissenbach J, Prat A, Krempf M, 
Junien C, Seidah NG, Boileau C (2003) Mutations in PCSK9 cause autosomal dominant 
hypercholesterolemia. Nat Genet 34: 154-6 
Acton S, Rigotti A, Landschulz KT, Xu S, Hobbs HH, Krieger M (1996) Identification of 
scavenger receptor SR-BI as a high density lipoprotein receptor. Science 271: 518-20 
Ahn YI, Kamboh MI, Aston CE, Ferrell RE, Hamman RF (1994) Role of common genetic 
polymorphisms in the LDL receptor gene in affecting plasma cholesterol levels in the 
general population. Arterioscler Thromb 14: 663-70 
Arca M, Zuliani G, Wilund K, Campagna F, Fellin R, Bertolini S, Calandra S, Ricci G, 
Glorioso N, Maioli M, Pintus P, Carru C, Cossu F, Cohen J, Hobbs HH (2002) Autosomal 
recessive hypercholesterolaemia in Sardinia, Italy, and mutations in ARH: a clinical and 
molecular genetic analysis. Lancet 359: 841-7 
Aronow B, Lattier D, Silbiger R, Dusing M, Hutton J, Jones G, Stock J, McNeish J, Potter 
S, Witte D, et al. (1989) Evidence for a complex regulatory array in the first intron of the 
human adenosine deaminase gene. Genes Dev 3: 1384-400 
Austin MA, Hutter CM, Zimmern RL, Humphries SE (2004) Familial hypercholesterolemia 
and coronary heart disease: a HuGE association review. Am J Epidemiol 160: 421-9 
Banares VG, Peterson G, Aguilar D, Gulayin R, Sisu E, Wyszynski DF, Pivetta OH, Tavella 
MJ (2005) Association between the APOE*4 allele and atherosclerosis is age dependent 
among Argentine males. Hum Biol 77: 247-56 
Banerji J, Olson L, Schaffner W (1983) A lymphocyte-specific cellular enhancer is located 
downstream of the joining region in immunoglobulin heavy chain genes. Cell 33: 729-40 
Basler K, Siegrist P, Hafen E (1989) The spatial and temporal expression pattern of 
sevenless is exclusively controlled by gene-internal elements. Embo J 8: 2381-6 
Benjannet S, Rhainds D, Essalmani R, Mayne J, Wickham L, Jin W, Asselin MC, Hamelin 
J, Varret M, Allard D, Trillard M, Abifadel M, Tebon A, Attie AD, Rader DJ, Boileau C, 
Brissette L, Chretien M, Prat A, Seidah NG (2004) NARC-1/PCSK9 and its natural mutants: 
zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL 
cholesterol. J Biol Chem 279: 48865-75 
Benjannet S, Rhainds D, Hamelin J, Nassoury N, Seidah NG (2006) The proprotein 
convertase (PC) PCSK9 is inactivated by furin and/or PC5/6A: functional consequences of 
natural mutations and post-translational modifications. J Biol Chem 281: 30561-72 
  131 
Benn M, Nordestgaard BG, Jensen JS, Nilausen K, Meinertz H, Tybjaerg-Hansen A (2005) 
Mutation in apolipoprotein B associated with hypobetalipoproteinemia despite decreased 
binding to the low density lipoprotein receptor. J Biol Chem 280: 21052-60 
Berge KE, Ose L, Leren TP (2006) Missense mutations in the PCSK9 gene are associated 
with hypocholesterolemia and possibly increased response to statin therapy. Arterioscler 
Thromb Vasc Biol 26: 1094-100 
Boerwinkle E, Visvikis S, Welsh D, Steinmetz J, Hanash SM, Sing CF (1987) The use of 
measured genotype information in the analysis of quantitative phenotypes in man. II. The 
role of the apolipoprotein E polymorphism in determining levels, variability, and 
covariability of cholesterol, betalipoprotein, and triglycerides in a sample of unrelated 
individuals. Am J Med Genet 27: 567-82 
 
Boerwinkle E, Utermann G (1988) Simultaneous effects of the apolipoprotein E 
polymorphism on apolipoprotein E, apolipoprotein B, and cholesterol metabolism. Am J 
Hum Genet 42: 104-12 
Bouthillier D, Sing CF, Davignon J (1983) Apolipoprotein E phenotyping with a single gel 
method: application to the study of informative matings. J Lipid Res 24: 1060-9 
 
Brown SA, Hutchinson R, Morrisett J, Boerwinkle E, Davis CE, Gotto AM, Jr., Patsch W 
(1993) Plasma lipid, lipoprotein cholesterol, and apoprotein distributions in selected US 
communities.  
Boright AP, Connelly PW, Brunt JH, Morgan K, Hegele RA (1998) Association and linkage 
of LDLR gene variation with variation in plasma low density lipoprotein cholesterol. J Hum 
Genet 43: 153-9 
 
Briggs MR, Yokoyama C, Wang X, Brown MS, Goldstein JL (1993) Nuclear protein that 
binds sterol regulatory element of low density lipoprotein receptor promoter. I. Identification 
of the protein and delineation of its target nucleotide sequence. J Biol Chem 268: 14490-6 
Brown SA, Hutchinson R, Morrisett J, Boerwinkle E, Davis CE, Gotto AM Jr, Patsch W 
(1993) Plasma lipid, lipoprotein cholesterol, and apoprotein distributions in selected US 
communities. The Atherosclerosis Risk in Communities (ARIC) Study. Arterioscler Thromb 
13:1139-1158. 
 
Burnett JR, Shan J, Miskie BA, Whitfield AJ, Yuan J, Tran K, McKnight CJ, Hegele RA, 
Yao Z (2003) A novel nontruncating APOB gene mutation, R463W, causes familial 
hypobetalipoproteinemia. J Biol Chem 278: 13442-52 
Burnett JR, Zhong S, Jiang ZG, Hooper AJ, Fisher EA, McLeod RS, Zhao Y, Barrett PH, 
Hegele RA, van Bockxmeer FM, Zhang H, Vance DE, McKnight CJ, Yao Z (2007) 
Missense mutations in APOB within the betaalpha1 domain of human APOB-100 result in 
  132 
impaired secretion of ApoB and ApoB-containing lipoproteins in familial 
hypobetalipoproteinemia. J Biol Chem 282: 24270-83 
Cameron J, Holla OL, Ranheim T, Kulseth MA, Berge KE, Leren TP (2006) Effect of 
mutations in the PCSK9 gene on the cell surface LDL receptors. Hum Mol Genet 15: 1551-8 
Chen SN, Ballantyne CM, Gotto AM, Jr., Tan Y, Willerson JT, Marian AJ (2005) A 
common PCSK9 haplotype, encompassing the E670G coding single nucleotide 
polymorphism, is a novel genetic marker for plasma low-density lipoprotein cholesterol 
levels and severity of coronary atherosclerosis. J Am Coll Cardiol 45: 1611-9 
   Chen JM, Ferec C, Cooper DN (2006) A systematic analysis of disease-associated variants 
in the 3' regulatory regions of human protein-coding genes I: general principles and 
overview. Hum Genet 120:1-21. 
 
Conne B, Stutz A, Vandli JD (2000) The 3' untranslated region of messenger RNA: a 
molecular 'hotspot' for pathology. Nature Med 6:637-641.  
 
Cheng D, Huang R, Lanham IS, Cathcart HM, Howard M, Corder EH, Poduslo SE (2005) 
Functional interaction between APOE4 and LDL receptor isoforms in Alzheimer's disease. J 
Med Genet 42: 129-31 
 
Chung S, Perry RP (1989) Importance of introns for expression of mouse ribosomal protein 
gene rpL32. Mol Cell Biol 9: 2075-82 
Cohen J, Pertsemlidis A, Kotowski IK, Graham R, Garcia CK, Hobbs HH (2005) Low LDL 
cholesterol in individuals of African descent resulting from frequent nonsense mutations in 
PCSK9. Nat Genet 37: 161-5 
Corbo RM, Scacchi R (1999) Apolipoprotein E (APOE) allele distribution in the world. Is 
APOE*4 a 'thrifty' allele? Ann Hum Genet 63: 301-10 
Davignon J, Gregg RE, Sing CF (1988) Apolipoprotein E polymorphism and 
atherosclerosis. Arteriosclerosis 8: 1-21 
Dawson PA, Hofmann SL, van der Westhuyzen DR, Sudhof TC, Brown MS, Goldstein JL 
(1988) Sterol-dependent repression of low density lipoprotein receptor promoter mediated 
by 16-base pair sequence adjacent to binding site for transcription factor Sp1. J Biol Chem 
263: 3372-9 
Dawson PA, Rudel LL (1999) Intestinal cholesterol absorption. Curr Opin Lipidol 10: 315-
20 
DeLong CJ, Smith WL (2005) An intronic enhancer regulates cyclooxygenase-1 gene 
expression. Biochem Biophys Res Commun 338: 53-61 
 
Frederickson RM, et al., (1989) 5'flanking and first intron sequences of the human beta -
actin gene required for efficient promotor activity. Nucleic Acids Res 17(1): 253-70 
  133 
Fasano T, Cefalu AB, Di Leo E, Noto D, Pollaccia D, Bocchi L, Valenti V, Bonardi R, 
Guardamagna O, Averna M, Tarugi P (2007) A novel loss of function mutation of PCSK9 
gene in white subjects with low-plasma low-density lipoprotein cholesterol. Arterioscler 
Thromb Vasc Biol 27: 677-81 
Garcia CK, Wilund K, Arca M, Zuliani G, Fellin R, Maioli M, Calandra S, Bertolini S, 
Cossu F, Grishin N, Barnes R, Cohen JC, Hobbs HH (2001) Autosomal recessive 
hypercholesterolemia caused by mutations in a putative LDL receptor adaptor protein. 
Science 292: 1394-8 
Garuti R, Jones C, Li WP, Michaely P, Herz J, Gerard RD, Cohen JC, Hobbs HH (2005) 
The modular adaptor protein autosomal recessive hypercholesterolemia (ARH) promotes 
low density lipoprotein receptor clustering into clathrin-coated pits. J Biol Chem 280: 
40996-1004 
Gent J, Braakman I (2004) Low-density lipoprotein receptor structure and folding. Cell Mol 
Life Sci 61: 2461-70 
Goldstein JL, Brown MS (1984) Progress in understanding the LDL receptor and HMG-
CoA reductase, two membrane proteins that regulate the plasma cholesterol. J Lipid Res 25: 
1450-61 
 
Goldstein J, Hobbs H, Brown M (1995) Familial Hypercholesterolemia.  In Scriver CR, 
Beaudet AL, Sly WS, Valle D (Eds) The Metabolic and Molecular basis of inherited disease. 
7
th
 ed. McGraw-Hill, New York, NY USA, Vol II, pp 1981-2030.  
 
Gotto AM Jr (1994) Heart disease in the assessment and treatment of hypercholesterolemia: 
coronary artery disease and other atherosclerotic disease, family history, and left ventricular 
hypertrophy. Am J Med 96:9S-18S.  
 
Gregori C, Porteu A, Lopez S, Kahn A, Pichard AL (1998) Characterization of the aldolase 
B intronic enhancer. J Biol Chem 273: 25237-43 
 
Gyrd-Hansen M, Krag TO, Rosmarin AG, Khurana TS (2002) Sp1 and the ets-related 
transcription factor complex GABP alpha/beta functionally cooperate to activate the 
utrophin promoter. J Neurol Sci 197: 27-35 
 
Hallman DM, Boerwinkle E, Saha N, Sandholzer C, Menzel HJ, Csazar A, Utermann G 
(1991) The apolipoprotein E polymorphism: a comparison of allele frequencies and effects 
in nine populations. Am J Hum Genet 49: 338-49 
He G, Gupta S, Yi M, Michaely P, Hobbs HH, Cohen JC (2002) ARH is a modular adaptor 
protein that interacts with the LDL receptor, clathrin, and AP-2. J Biol Chem 277: 44044-9 
Hobbs HH, Brown MS, Goldstein JL (1992) Molecular genetics of the LDL receptor gene in 
familial hypercholesterolemia. Hum Mutat 1: 445-66 
  134 
Hobbs HH, Russell DW, Brown MS, Goldstein JL (1990) The LDL receptor locus in 
familial hypercholesterolemia: mutational analysis of a membrane protein. Ann Rev Genet 
24:133-170.   
 
Hobbs HH, Leitersdorf E, Goldstein JL, Brown MS, Russell DW (1988) Multiple crm- 
mutations in familial hypercholesterolemia. Evidence for 13 alleles, including four deletions. 
J Clin Invest 81: 909-17 
Horton JD, Cohen JC, Hobbs HH (2007) Molecular biology of PCSK9: its role in LDL 
metabolism. Trends Biochem Sci 32: 71-7 
Hua X, Yokoyama C, Wu J, Briggs MR, Brown MS, Goldstein JL, Wang X (1993) SREBP-
2, a second basic-helix-loop-helix-leucine zipper protein that stimulates transcription by 
binding to a sterol regulatory element. Proc Natl Acad Sci U S A 90: 11603-7 
Huang LS, Kayden H, Sokol RJ, Breslow JL (1991) ApoB gene nonsense and splicing 
mutations in a compound heterozygote for familial hypobetalipoproteinemia. J Lipid Res 32: 
1341-8 
Humphries S, Coviello DA, Masturzo P, Balestreri R, Orecchini G, Bertolini S (1991) 
Variation in the low density lipoprotein receptor gene is associated with differences in 
plasma low density lipoprotein cholesterol levels in young and old normal individuals from 
Italy. Arterioscler Thromb 11: 509-16 
Hussain MM, Strickland DK, Bakillah A (1999) The mammalian low-density lipoprotein 
receptor family. Annu Rev Nutr 19: 141-72 
 
Hinds DA, Stuve LL, Nilsen GB, Halperin E, Eskin E, Ballinger DG, Frazer KA, Cox DR 
(2005) Whole-genome patterns of common DNA variation in three human populations. 
Science 307:1072-1079.  
 
Innerarity TL, Mahley RW, Weisgraber KH, Bersot TP, Krauss RM, Vega GL, Grundy SM, 
Friedl W, Davignon J, McCarthy BJ (1990) Familial defective apolipoprotein B-100: a 
mutation of apolipoprotein B that causes hypercholesterolemia. J Lipid Res 31: 1337-49 
Jacobsen N, Fenger M, Bentzen J, Rasmussen SL, Jakobsen MH, Fenstholt J, Skouv J 
(2002) Genotyping of the apolipoprotein B R3500Q mutation using immobilized locked 
nucleic acid capture probes. Clin Chem 48: 657-60 
 
Kakoki M, Tsai YS, Kim HS, Hatada S, Ciavatta DJ, Takahashi N, Arnold LW, Maeda N, 
Smithies O (2004) Altering the expression in mice of genes by modifying their 3' regions. 
Dev Cell 6:597-606 
Knoblauch H, Bauerfeind A, Krahenbuhl C, Daury A, Rohde K, Bejanin S, Essioux L, 
Schuster H, Luft FC, Reich JG (2002) Common haplotypes in five genes influence genetic 
  135 
variance of LDL and HDL cholesterol in the general population. Hum Mol Genet 11: 1477-
85 
 
Knoblauch H, Bauerfeind A, Toliat MR, Becker C, Luganskaja T, Gunther UP, Rohde K, 
Schuster H, Junghans C, Luft FC, Nurnberg P, Reich JG (2004) Haplotypes and SNPs in 13 
lipid-relevant genes explain most of the genetic variance in high-density lipoprotein and 
low-density lipoprotein cholesterol. Hum Mol Genet 13: 993-1004 
 
K Satyamoorthy, S J Samulewicz, L D Thornburg, A Basu, Howe aCC (1977) Identification 
of an intronic enhancer that nullifies upstream repression of SPARC gene expression. 
Nucleic Acids Research 25: 3169-3174 
 
Kim HS, Smithies O, Maeda N (1990) A physical map of the human salivary proline-rich 
protein gene cluster covers over 700 kbp of DNA. Genomics 6: 260-7 
 
Klausen IC, Hansen PS, Gerdes LU, Rudiger N, Gregersen N, Faergeman O (1993) A PvuII 
polymorphism of the low density lipoprotein receptor gene is not associated with plasma 
concentrations of low density lipoproteins including LP(a). Hum Genet 91: 193-5 
Knouff C, Malloy S, Wilder J, Altenburg MK, Maeda N (2001) Doubling expression of the 
low density lipoprotein receptor by truncation of the 3'-untranslated region sequence 
ameliorates type iii hyperlipoproteinemia in mice expressing the human apoe2 isoform. J 
Biol Chem 276: 3856-62 
Kotowski IK, Pertsemlidis A, Luke A, Cooper RS, Vega GL, Cohen JC, Hobbs HH (2006) 
A spectrum of PCSK9 alleles contributes to plasma levels of low-density lipoprotein 
cholesterol. Am J Hum Genet 78: 410-22 
Kypreos K, Li X, Dijk Kv, Havekes L, Zannis V ( 2003.) Molecular mechanisms of type III 
hyperlipoproteinemia: The contribution of the carboxy-terminal domain of ApoE can 
account for the dyslipidemia that is associated with the E2/E2 phenotype. Biochemistry. 
42(33): 9841-53 
Lagace TA, Curtis DE, Garuti R, McNutt MC, Park SW, Prather HB, Anderson NN, Ho 
YK, Hammer RE, Horton JD (2006) Secreted PCSK9 decreases the number of LDL 
receptors in hepatocytes and in livers of parabiotic mice. J Clin Invest 116: 2995-3005 
 
Lancellotti S, Di Leo E, Penacchioni JY, Balli F, Viola L, Bertolini S, Calandra S, Tarugi P 
(2004) Hypobetalipoproteinemia with an apparently recessive inheritance due to a "de novo" 
mutation of apolipoprotein B. Biochim Biophys Acta 1688: 61-7 
Leren TP (2004) Mutations in the PCSK9 gene in Norwegian subjects with autosomal 
dominant hypercholesterolemia. Clin Genet 65: 419-22 
Levy E, Minnich A, Cacan SL, Thibault L, Giroux LM, Davignon J, Lambert M (1997) 
Association of an exon 3 mutation (Trp66-->Gly) of the LDL receptor with variable 
  136 
expression of familial hypercholesterolemia in a French Canadian family. Biochem Mol 
Med 60: 59-69 
Linton MF, Pierotti V, Young SG (1992) Reading-frame restoration with an apolipoprotein 
B gene frameshift mutation. Proc Natl Acad Sci U S A 89: 11431-5 
Lund-Katz S, Wehrli S, Zaiou M, Newhouse Y, Weisgraber KH, Phillips MC (2001) Effects 
of polymorphism on the microenvironment of the LDL receptor-binding region of human 
apoE. J Lipid Res 42: 894-901 
Leitersdorf E, Hobbs HH (1988) Human LDL receptor gene: HincII polymorphism detected 
by gene amplification. Nucleic Acids Res 16: 7215 
 
Maeda N, Bliska JB, Smithies O (1983) Recombination and balanced chromosome 
polymorphism suggested by DNA sequences 5' to the human delta-globin gene. Proc Natl 
Acad Sci USA 80:5012-5016.  
 
Maeda N (1991) DNA polymorphisms in the controlling region of the human haptoglobin 
genes: a molecular explanation for the haptoglobin 2-1 modified phenotype. Am J Hum 
Genet 49:158-166.  
 
Mack CP, Owens GK (1999) Regulation of smooth muscle alpha-actin expression in vivo is 
dependent on CArG elements within the 5' and first intron promoter regions. Circ Res 84: 
852-61 
 
Martino A, Holmes JHt, Lord JD, Moon JJ, Nelson BH (2001) Stat5 and Sp1 regulate 
transcription of the cyclin D2 gene in response to IL-2. J Immunol 166: 1723-9 
 
Mahley RW, Ji ZS (1999) Remnant lipoprotein metabolism: key pathways involving cell-
surface heparan sulfate proteoglycans and apolipoprotein E. J Lipid Res 40: 1-16 
Malloy I AM, Knouff C, Lanningham-Foster L, Parks S, Maeda N (2004) harmful effect of 
increased LDLR expression in mice with human Apo E*4 but not Apo E*3. Arterioscler 
Throm Vasc Biol. January 2004:91-97.: 91-97 
Maxwell KN, Breslow JL (2004) Adenoviral-mediated expression of Pcsk9 in mice results 
in a low-density lipoprotein receptor knockout phenotype. Proc Natl Acad Sci U S A 101: 
7100-5 
Maxwell KN, Fisher EA, Breslow JL (2005) Overexpression of PCSK9 accelerates the 
degradation of the LDLR in a post-endoplasmic reticulum compartment. Proc Natl Acad Sci 
U S A 102: 2069-74 
Melman L, Geuze H, Li Y, McCormick L, Kerkhof PV, Strous G, Schwartz A, Bu G ( 2002) 
Proteasome regulates the delivery of LDL receptor-related protein into the degradation 
pathway. Mol Biol Cell Sep;13(9): 3325-35 
  137 
Michael K. Altenburg, Sudi IM, Chris Knouff, John SP, Maeda N (2004) ApoE4 trapping by 
the low density lipoprotein receptor. ELSEVIER 1262: 388-391 
Moore JH, Williams SM (2002) New strategies for identifying gene-gene interactions in 
hypertension. Ann Med 34: 88-95 
 
Muallem H, North KE, Kakoki M, Wojczynski MK, Li X, Grove M, Boerwinkle E, 
Wilhelmsen KC, Heiss G, Maeda N (2007) Quantitative effects of common genetic 
variations in the 3'UTR of the human LDL-receptor gene and their associations with plasma 
lipid levels in the Atherosclerosis Risk in Communities study. Hum Genet 121: 421-31 
 
Naureckiene S, Ma L, Sreekumar K, Purandare U, Lo CF, Huang Y, Chiang LW, Grenier 
JM, Ozenberger BA, Jacobsen JS, Kennedy JD, DiStefano PS, Wood A, Bingham B (2003) 
Functional characterization of Narc 1, a novel proteinase related to proteinase K. Arch 
Biochem Biophys 420: 55-67 
 
Oshima RG, Abrams L, Kulesh D (1990) Activation of an intron enhancer within the keratin 
18 gene by expression of c-fos and c-jun in undifferentiated F9 embryonal carcinoma cells. 
Genes Dev 4: 835-48 
Panagiotakos DB, Pitsavos C, Skoumas J, Chrysohoou C, Toutouza M, Stefanadis 
CI,Toutouzas PK (2003) Importance of LDL/HDL cholesterol ratio as a predictor for 
coronary heart disease events in patients with heterozygous familial hypercholesterolaemia: 
a 15-year follow-up (1987-2002). Curr Med Res Opin 19:89- 
94. 
 
Pedersen JC, Berg K (1989) Interaction between low density lipoprotein receptor (LDLR) 
and apolipoprotein E (apoE) alleles contributes to normal variation in lipid level. Clin Genet 
35: 331-7 
 
Pedersen JC, Berg K (1990) Gene-gene interaction between the low density lipoprotein 
receptor and apolipoprotein E loci affects lipid levels. Clin Genet 38: 287-94 
 
Pedersen J, Berg K ( 1988) Normal DNA polymorphism at the low density lipoprotein 
receptor (LDLR) locus associated with serum cholesterol level. Clin Genet. 34(5): 306-12 
Pereira E, Ferreira R, Hermelin B, Thomas G, Bernard C, Bertrand V, Nassiff H, Mendez 
del Castillo D, Bereziat G, Benlian P (1995) Recurrent and novel LDL receptor gene 
mutations causing heterozygous familial hypercholesterolemia in La Habana. Hum Genet 
96: 319-22 
Poledne R, Pisa Z, Berg K (1993) Normal genetic variation at the low density lipoprotein 
receptor (LDLR) locus influences cholesterol levels in children. Clin Genet 43: 122-6 
 
  138 
Poledne R, Pisa Z, Berg K (1993) Normal genetic variation at the low density lipoprotein 
receptor (LDLR) locus influences cholesterol levels in children. Clin Genet 43: 122-6 
Quinn MT, Parthasarathy S, Fong LG, Steinberg D (1987) Oxidatively modified low density 
lipoproteins: a potential role in recruitment and retention of monocyte/macrophages during 
atherogenesis. Proc Natl Acad Sci U S A 84: 2995-8 
Qiao L, Maclean PS, Schaack J, Orlicky DJ, Darimont C, Pagliassotti M, Friedman JE, Shao 
J (2005) C/EBPalpha regulates human adiponectin gene transcription through an intronic 
enhancer. Diabetes 54: 1744-54 
 
Qin H, Sun Y, Benveniste EN (1999) The transcription factors Sp1, Sp3, and AP-2 are 
required for constitutive matrix metalloproteinase-2 gene expression in astroglioma cells. J 
Biol Chem 274: 29130-7 
 
Ranade K, Chang MS, Ting CT, Pei D, Hsiao CF, Olivier M, Pesich R, Hebert J, Chen YD, 
Dzau VJ, Curb D, Olshen R, Risch N, Cox DR, Botstein D (2001) High-throughput 
genotyping with single nucleotide polymorphisms. Genome Res 11:1262-1268 
Reid LH, Gregg RG, Smithies O, Koller BH (1990) Regulatory elements in the introns of 
the human HPRT gene are necessary for its expression in embryonic stem cells. Proc Natl 
Acad Sci U S A 87: 4299-303 
 
Reddy CD, Reddy EP (1989) Differential binding of nuclear factors to the intron 1 
sequences containing the transcriptional pause site correlates with c-myb expression. Proc 
Natl Acad Sci U S A 86: 7326-30 
Reid LH, Gregg RG, Smithies O, Koller BH (1990) Regulatory elements in the introns of 
the human HPRT gene are necessary for its expression in embryonic stem cells. Proc Natl 
Acad Sci U S A 87: 4299-303 
Rippe RA, Lorenzen SI, Brenner DA, Breindl M (1989) Regulatory elements in the 5'-
flanking region and the first intron contribute to transcriptional control of the mouse alpha 1 
type I collagen gene. Mol Cell Biol 9: 2224-7 
Rudel LL, Parks JS, Johnson FL, Babiak J (1986) Low density lipoproteins in 
atherosclerosis. J Lipid Res 27: 465-74 
Saito H, Dhanasekaran P, Baldwin F, Weisgraber KH, Phillips MC, Lund-Katz S (2003) 
Effects of polymorphism on the lipid interaction of human apolipoprotein E. J Biol Chem 
278: 40723-9 
Salazar LA, Cavalli SA, Hirata MH, Diament J, Forti N, Giannini SD, Nakandakare ER, 
Bertolami MC, Hirata RD (2000) Polymorphisms of the low-density lipoprotein receptor 
gene in Brazilian individuals with heterozygous familial hypercholesterolemia. Braz J Med 
Biol Res 33: 1301-4 
  139 
Salazar LA, Hirata MH, Forti N, Diament j, Giannini SD, Jaqueline IS, Hirata RD (2000) 
PvuII intron 15 polymorphism at the LDL receptor gene is associated with differences in 
serum lipid concentrations in subjects with low and high risk for coronary artery disease 
from Brazil. Clinica Chimi Acta 293:75-88.  
 
Stephens M, Smith NJ, Donnelly P (2001) A new statistical method for haplotype 
reconstruction from population data. Am J Hum Genet 68:978-989. 
 
Stephens M, Donnelly P (2003) A comparison of bayesian methods for haplotype 
reconstruction from population genotype data. Am J Hum Genet 73:1162-1169. 
 
Smith JR, Osborne TF, Goldstein JL, Brown MS (1990) Identification of nucleotides 
responsible for enhancer activity of sterol regulatory element in low density lipoprotein 
receptor gene. J Biol Chem 265: 2306-10 
 
Sturgeon JD, Folsom AR, Bray MS, Boerwinkle E, Ballantyne CM (2005) Apolipoprotein E 
genotype and incident ischemic stroke: the Atherosclerosis Risk in Communities Study. 
Stroke 36: 2484-6 
 
Schonfeld G (2003) Familial hypobetalipoproteinemia: a review. J Lipid Res 44: 878-83 
Schuster H, Humphries S, Rauh G, Held C, Keller C, Wolfram G, Zollner N (1990) 
Association of DNA-haplotypes in the human LDL-receptor gene with normal serum 
cholesterol levels. Clin Genet 38: 401-9 
Seidah NG, Benjannet S, Wickham L, Marcinkiewicz J, Jasmin SB, Stifani S, Basak A, Prat 
A, Chretien M (2003) The secretory proprotein convertase neural apoptosis-regulated 
convertase 1 (NARC-1): liver regeneration and neuronal differentiation. Proc Natl Acad Sci 
U S A 100: 928-33 
Sing C, Davignon J (1985) Role of the apolipoprotein E polymorphism 
in determining normal plasma lipid and lipoprotein variation. Am J Hum Genet 37: 268–85 
Smith JR, Osborne TF, Goldstein JL, Brown MS (1990) Identification of nucleotides 
responsible for enhancer activity of sterol regulatory element in low density lipoprotein 
receptor gene. J Biol Chem 265: 2306-10 
Soria LF, Ludwig EH, Clarke HR, Vega GL, Grundy SM, McCarthy BJ (1989) Association 
between a specific apolipoprotein B mutation and familial defective apolipoprotein B-100. 
Proc Natl Acad Sci U S A 86: 587-91 
Soutar AK, Naoumova RP, Traub LM (2003) Genetics, clinical phenotype, and molecular 
cell biology of autosomal recessive hypercholesterolemia. Arterioscler Thromb Vasc Biol 
23: 1963-70 
Steinberg D (1996) A docking receptor for HDL cholesterol esters. Science 271: 460-1 
  140 
Sudhof TC, Goldstein JL, Brown MS, Russell DW (1985) The LDL receptor gene: a mosaic 
of exons shared with different proteins. Science 228: 815-22 
Sudhof TC, Van der Westhuyzen DR, Goldstein JL, Brown MS, Russell DW (1987) Three 
direct repeats and a TATA-like sequence are required for regulated expression of the human 
low density lipoprotein receptor gene. J Biol Chem 262: 10773-9 
Tall AR (1990) Plasma high density lipoproteins. Metabolism and relationship to 
atherogenesis. J Clin Invest 86: 379-84 
Taylor R JM, Seed M, Humphries S. (1988) Four DNA polymorphisms in the LDL receptor 
gene: their genetic relationship and use in the study of variation at the LDL receptor locus. 
J Med Genet. 1988 Oct;25(10):653-9. . J Med Genet. 25(10): 653-9. 
Timms KM, Wagner S, Samuels ME, Forbey K, Goldfine H, Jammulapati S, Skolnick MH, 
Hopkins PN, Hunt SC, Shattuck DM (2004) A mutation in PCSK9 causing autosomal-
dominant hypercholesterolemia in a Utah pedigree. Hum Genet 114: 349-53 
Tolleshaug H, Goldstein JL, Schneider WJ, Brown MS (1982) Posttranslational processing 
of the LDL receptor and its genetic disruption in familial hypercholesterolemia. Cell 30: 
715-24 
Tybjaerg-Hansen A, Steffensen R, Meinertz H, Schnohr P, Nordestgaard BG (1998) 
Association of mutations in the apolipoprotein B gene with hypercholesterolemia and the 
risk of ischemic heart disease. N Engl J Med 338: 1577-84 
Templeton AR (1987) The general relationship between average effect and average excess. 
Genet Res 49: 69-70 
The ARIC investigators (1989) The Atherosclerosis Risk in Communities (ARIC) Study: 
design and objectives. Am J Epidemiol 129:687-702. 
 
Van Aalst-Cohen ES, Jansen AC, De Jongh S, De Sauvage Nolting PR, Kastelein JJ (2004) 
Clinical, diagnostic, and therapeutic aspects of familial hypercholesterolemia. Semin Vasc 
Med 4: 31-41 
Wang QF, Prabhakar S, Wang Q, Moses AM, Chanan S, Brown M, Eisen MB, Cheng JF, 
Rubin EM, Boffelli D (2006) Primate-specific evolution of an LDLR enhancer. Genome 
Biol 7: R68 
Wang X, Sato R, Brown MS, Hua X, Goldstein JL (1994) SREBP-1, a membrane-bound 
transcription factor released by sterol-regulated proteolysis. Cell 77: 53-62 
Wang S, Zhao H (2003) Sample size needed to detect gene-gene interactions using 
association designs. Am J Epidemiol 158: 899-914 
 
  141 
Weisgraber KH (1994) Apolipoprotein E : structure-function relationship. .Adv protein  
Chem.: 249-302 
 
Weisgraber KH (1990) Apolipoprotein E distribution among human plasma lipoproteins: 
role of the cysteine-arginine interchange at residue 112. J Lipid Res 31: 1503-1 
Wilson GM, Vasa MZ, Deeley RG (1998) Stabilization and cytoskeletal-association of LDL 
receptor mRNA are mediated by distinct domains in its 3' untranslated region. J Lipid Res 
39:1025-1032.  
 
Willer CJ, Sanna S, Jackson AU, Scuteri A, Bonnycastle LL, Clarke R, Heath SC, Timpson 
NJ, Najjar SS, Stringham HM, Strait J, Duren WL, Maschio A, Busonero F, Mulas A, Albai 
G, Swift AJ, Morken MA, Narisu N, Bennett D, Parish S, Shen H, Galan P, Meneton P, 
Hercberg S, Zelenika D, Chen WM, Li Y, Scott LJ, Scheet PA, Sundvall J, Watanabe RM, 
Nagaraja R, Ebrahim S, Lawlor DA, Ben-Shlomo Y, Davey-Smith G, Shuldiner AR, Collins 
R, Bergman RN, Uda M, Tuomilehto J, Cao A, Collins FS, Lakatta E, Lathrop GM, 
Boehnke M, Schlessinger D, Mohlke KL, Abecasis GR (2008) Newly identified loci that 
influence lipid concentrations and risk of coronary artery disease. Nat Genet 40: 161-9 
 
Yamamoto T, Davis CG, Brown MS, Schneider WJ, Casey ML, Goldstein JL, Russell DW 
(1984) The human LDL receptor: a cysteine-rich protein with multiple Alu sequences in its 
mRNA. Cell 39: 27-38 
Zhao Z, Tuakli-Wosornu Y, Lagace TA, Kinch L, Grishin NV, Horton JD, Cohen JC, Hobbs 
HH (2006) Molecular characterization of loss-of-function mutations in PCSK9 and 
identification of a compound heterozygote. Am J Hum Genet 79: 514-23 
Zhu H, Tucker HM, Grear KE, Simpson JF, Manning AK, Cupples LA, Estus S (2007) A 
common polymorphism decreases low-density lipoprotein receptor exon 12 splicing 
efficiency and associates with increased cholesterol. Hum Mol Genet 16: 1765-72 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
